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ABSTRACT 
Characteristics and patterns of opioid-related overdoses among veterans 
Sara C. Warfield 
BACKGROUND AND OBJECTIVES: The United States is in the midst of an opioid overdose 
crisis and is now considered a public health emergency. Given the alarming rise in opioid 
overdose deaths, there is an urgent need to understand the characteristics and risks associated 
with opioid overdoses. The objectives of this study were 1) to compare factors associated with 
different type of opioid overdose, 2) to determine the conditional probability of repeat overdose 
among veterans with a prior overdose event and corresponding probability of mortality for each 
overdose event and, 3) to identify cause-specific mortality rate of those who experienced a 
nonfatal overdose during our study period.  
METHODS: Using clinical records and mortality files of more than 10.5 million veterans, we 
extracted data among those with a documented opioid overdose between January 1, 2011 and 
December 31, 2015. During this time, 13,333 veterans had at least one documented opioid 
overdose of any intent.  
RESULTS: Study 1. Patients who were younger in age (18-44 OR [odds ratio] 7.19, 45-64 OR 
4.78) had significantly higher odds of a fatal index overdose and experiencing a repeat overdose 
(18-44 OR 2.13, 45-64 OR 1.78). Having one or more chronic pain diagnoses was both 
associated with experiencing a fatal index overdose (OR 3.96) or repeat overdose (OR 1.15). A 
diagnosis associated with mental health or substance abuse or dependence was significantly 
associated with experiencing a repeat overdose, (OR 1.54 and 1.25 respectively).  Receipt of 
medication-assisted therapy (MAT) more than one year prior (OR 1.28) to the first (i.e. index) 
overdose was significantly associated with increased odds of a fatal overdose whereas receiving 
counseling services prior to index overdose was protective of experiencing a fatal index 
overdose. Study 2. One fifth of the study sample had a repeat overdose during the study period, 
with a conditional probability that increased linearly for each subsequent overdose event. The 
conditional probability of repeat overdose went from 21.1% on the second overdose to 43.2% for 
five or more overdoses. Mortality was highest among the first documented overdose. Study 3. 
Overall, veterans with a prior nonfatal overdose more often died from any cause in comparison 
to their veteran peers and had approximately 26 times the mortality rate to the general U.S. 
population.  Veterans with a prior nonfatal overdose had a higher risk of death from substances 
(aHR [adjusted Hazard Ratio] 5.0, 95% CI [confidence interval]: 4.4-5.8), including a higher risk 
of death from drugs (aHR 6.9; 95% CI 5.8-8.1) and alcohol (aHR 2.7, 95% CI 2.1-3.6). For 
cause-specific mortalities assessed between veterans in our cohort and the general U.S. 
population, the standardized mortality rate ratio (SMR) was 114 times higher for deaths 
associated with substances (95% CI: 98.8-128.7), 107 times higher for deaths associated with 
hepatitis (95% CI: 65.5-152.7) and 68 times higher for deaths associated with liver cancers (95% 
CI: 47.9-88.7). Overall, veterans in our overdose cohort had an elevated mortality rate than the 
general public for all the specific causes of death assessed.  
CONCLUSION: Although risk factors for opioid overdoses are well studied, there appears to be 
differences between the type of opioid overdoses documented in a clinical setting. Given that 
mortality is highest on the first documented overdose suggests that prevention efforts should be 
further support to reach those patients at highest risk. Furthermore, given that the probability of 
experiencing a repeat overdose increases with each overdose event suggest that healthcare 
settings should be prepared to handle an influx in patients, specifically those with mental health 
diagnoses.  Moreover, given the elevated risk of death from all-causes, specifically those 
associated with substances suggests the need for an integrated healthcare approach. 
Understanding risks factors, type of overdose, and cause-specific mortality among patients with 
an opioid overdose could help to inform healthcare interventions and potentially lead to better 
patient outcomes.  
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Chapter 1. Introduction 
1.1 Background 
Opioid overdoses have surged in the past decade and deaths from overdose are now considered 
one of our country’s most serious public health crises. Between 2007 and 2017 there were more 
than 507,000 overdose deaths in the United States; with more than half of these involving 
opioids [1-4]. Concurrent with the rise in overdose deaths, hospitalizations related to opioid 
abuse and misuse have also been on the rise [5, 6]. Between 2009 and 2014, opioid overdoses 
resulting in inpatient hospital admission increased more than 60%, emergency department visits 
nearly doubled [5] and costs associated with overdose morbidity and mortality have been 
estimated to exceed $22 billion annually [7, 8].  
Despite the impact associated with opioid overdose on the healthcare system, few studies have 
examined information available from electronic health records in conjunction with vital records 
to examine risk for opioid overdose or to inform prevention and clinical programs. There are a 
number of unanswered questions related to the combinations of medical diagnoses and social 
conditions as potential risk factors for overdose, particularly among populations with evidence of 
abuse or misuse. To date, there have been a limited number of studies that examined the etiology 
of repeated opioid overdoses or compared them with characteristics associated with fatal 
overdose. [9-11]. Similarly, little is known about the patterns of cause-specific mortality risk 
among those with history of at least one nonfatal overdose [12, 13]. Understanding risk factors 
for repeated overdose and mortality following a nonfatal overdose could inform healthcare 
interventions and in turn, better patient outcomes.  
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1.1.1 Risk Factors for Overdose 
Individual-level risk factors for opioid overdose include sex (male), age (particularly 18 to 45 
years), race/ethnicity (non-Hispanic white), and residence in a rural area; particularly the 
Appalachian region [2, 3, 14-18]. Physical health conditions associated with an increased risk of 
overdose include diagnoses associated with chronic pain, liver disease, renal disease, chronic 
pulmonary disease, cardiovascular disease, musculoskeletal injury, cancer, and skin and soft-
tissue infections [19-22]. Mental health diagnoses and related factors associated with overdose 
risk include depression, anxiety , history of suicide attempt or ideation, post-traumatic stress 
disorder (PTSD), bipolar disorder, attention deficit disorder (ADD), frequent or severe 
psychological distress, and substance use disorder (SUD) [19-21, 23-27]. While many risk 
factors for overdoses have been previously studied, they have largely examined risk factors 
among people who inject drugs (PWID) or individuals taking prescription opioids; primarily due 
to chronic non-cancer pain [17, 22, 26, 28-32]. Moreover, a majority of studies have focused on 
identifying risk factors using information obtained from cross-sectional surveys. Risk factors 
associated with opioid overdose are detailed in Table 1. 
1.1.2 Epidemiology of Overdose and Veterans Who Use VHA Services 
Evidence suggests that risk factors associated with opioid overdose among veterans who have 
utilized Veterans Health Administration (VHA) services are similar to those identified among the 
general U.S. population. Risk factors assessed in previous studies include dosage of prescribed 
opioids, duration of prescribed opioids [20, 22, 25, 33] , medical conditions associated with 
chronic pain, and diagnoses or symptoms associated with psychiatric disorders [25, 34, 35]. 
Although risk factors for overdose are similar to those in the general population, research 
suggests that more veterans who use VHA services have history of some risk factors associated 
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with overdose morbidity and mortality, such as chronic pain and mental health diagnoses, which 
in turn may be associated with higher overdose mortality rate among members of this population 
[24, 36, 37]. Further, previous research among veterans found that over 60% of patients who 
experienced an unintentional opioid overdose were seen in an outpatient setting in the month 
prior to their overdose and approximately 30% of those were for mental health treatment [38, 
39]. While many risk factors for fatal overdose have been previously identified, existing studies 
largely examined unintentional overdose death or risk factors for overdose among those with 
access to prescription opioid pain relievers; primarily due to chronic pain [18, 20, 22, 25, 29, 35, 
40, 41]. Although medical diagnoses capture a variety of risk factors associated with overdose 
mortality, they do not capture all potential risk factors or information available from electronic 
medical records. Environmental and social stressors have been previously identified as risk 
factors for substance abuse, yet little is understood about the unique contribution of these factors 
or the combined influence of environmental and social stressors and medical/psychiatric 
diagnoses.  
Numerous studies have found that social determinants of health (SDoH) are often significantly 
associated with negative outcomes [42-44]. SDoH that are the most significant for health 
outcomes are often those associated with socioeconomic status, such as economic instability or 
inadequate housing [42, 45]. Factors such as homelessness and early life adversity, have also 
been shown to influence risk for drug use and mental health disorders [46, 47]. Indicators of 
social determinants of health can be assessed in electronic health records (EHR) through certain 
V codes (ICD-9) and Z codes (ICD-10). Although these social codes can be used in any 
healthcare setting, studies have shown they are generally underutilized by most healthcare 
professionals other than mental health professionals [44, 48].  
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Looking beyond the primary and secondary diagnostic codes may provide an opportunity to 
describe the social, behavioral, and environmental factors, also known as contextual factors, 
which may be associated with overdose risk [48-52]. Such findings could inform additional 
strategies designed to reduce overdose deaths attributed to opioids.  Although studies have 
examined outpatient visits prior to an overdose, no existing study has examined contextual 
factors prior to an overdose and few have identified these factors in conjunction with health 
diagnosis in the veteran population [38, 39].   
It is possible that previously identified risk factors may be exaggerated among veteran 
populations, such as mental health diagnoses (i.e. post-traumatic stress disorder (PTSD) or 
chronic pain [24, 25, 33, 34, 53]. Studies conducted using data from VHA records have 
consistently found that veterans have a high rate of mental health diagnoses, including substance 
use disorder (SUD),[20, 34, 53-55]; a potentially important risk factor to overdose morbidity and 
mortality[20, 24, 25, 36].  
1.1.3 VHA and Electronic Health Records 
Data from EHRs can be used in addition to mortality and prescribing surveillance systems to 
monitor trends as well as identify clinical characteristics associated with a myriad of health 
outcomes in a timely manner. EHRs hold a comprehensive list of healthcare factors such as 
diagnosis codes, procedure codes and medication data, allowing for a deeper understanding of 
various health outcomes. Linking clinical and death records together can leverage data between 
these two sources to enhance the understanding of corresponding risk for health outcomes. 
Findings from rich data sources like EHRs can inform future healthcare efforts targeting patients 
at risk for overdose.  
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Given the growing concern for opioid overdoses across the U.S., there is a need to enhance 
information used to understand risk for and prevention of overdose morbidity and mortality. 
Further, the majority of risk factors identified have focused on single episodes (either fatal or 
nonfatal) and comparatively little is known regarding the risk factors for repeated overdose.  
1.1.4 VHA population 
The VHA is one of the largest integrated healthcare system in the United States and collects data 
on clinical diagnosis, procedures, medications, and sociodemographic information from more 
than six million patients annually. Currently, the largest proportion of veterans receiving VHA 
medical care served in the Vietnam Era [56].  
Serving more than six million patients annually, the VHA provides an array of comprehensive 
healthcare services for a myriad of health conditions. VHA services are provided in 170 medical 
centers and 1,243 outpatient clinics throughout the U.S. [56]. Available data suggests that 
patients seeking care from the VHA often have poorer health outcomes, such as chronic pain and 
psychiatric comorbidities, and multi-system diagnoses, which could increase risk of negative 
health outcomes [57, 58]. In 2003, it was estimated that more than one million veterans who use 
VHA services have been diagnosed with either a substance abuse disorder or other mental health 
condition [59]. Accordingly, mental health and substance use disorders are considered a 
significant issue among the veteran population [60, 61]. Previous research suggests that more 
than 55,000 veterans who use VHA services have been diagnosed with an opioid use disorder 
(OUD)[62]. The breadth of data collected by the VHA coupled with the evidence of elevated risk 
factors among the patient population provides a unique opportunity to use information from this 
health care system to identify previously unexplored risk factors and targeted strategies to reduce 
opioid-related morbidity and mortality.  
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1.1.5 Current Prevention Efforts 
Primary prevention strategies for opioid abuse and overdose prevention have largely focused on 
reducing the excess supply of prescription opioids, including the development and support of 
safe prescribing guidelines and the implementation of prescription drug monitoring programs 
(PDMP). Secondary and tertiary efforts have been primarily focused on addressing the gap in 
treatment and distribution of naloxone, a rapid acting opioid antagonist [63-65].  Importantly, 
one consequence of the increased distribution and resulting availability of naloxone is the 
associated increase in probability of surviving an overdose and related history of multiple 
overdoses. 
In recent years, the VHA has amplified efforts to reduce risk of opioid overdose among patients 
receiving care from clinicians in its facilities. In an effort to promote safer prescribing the VHA 
introduced the Opioid Safety Initiative (OSI) which leverages prescription data within the VHA 
and helps clinicians identify patients at risk for adverse risks from opioids. In addition to the 
OSI, the VHA developed a dashboard to identify patients at risk for an adverse event related to 
opioids [63, 66]. Furthermore, the VHA has developed academic detailing on opioid abuse and 
overdose prevention in an effort to provide health care professionals with evidence-based 
educational tools [66]. To further reduce the burden of opioid overdose among veterans, the U.S. 
Department of Veterans Affairs also developed the Opioid Overdose Education and Naloxone 
Distribution (OEND) program. This program primarily focuses on educating health care 
professionals and high-risk patients on strategies to prevent, identify, and reverse an opioid 
overdose. Veterans with a history of injection drug use, substance use such as heroin, a diagnosis 
of opioid use disorder (OUD), or those with a high likelihood of opioid overdose or witnessing 
an overdose are targeted for the OEND program. These patients’ are often identified in medical 
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settings including but not limited to treatment programs such as Medication-Assisted Treatment 
(MAT), inpatient withdrawal management, syringe access programs, emergency departments, 
homeless shelters and other primary health care settings[67].  
1.2 Purpose Statement 
Given increases in overdose deaths, there is a need to identify opportunities for intervention and 
prevention services informed by a better understanding of risk for repeat overdose and mortality. 
The primary aim of this study is to identify and assess the risk factors such as demographic 
characteristics, medical diagnoses and indicators of social determinants of health associated with 
risk for repeat overdose and all-cause mortality among patients with a history of one opioid 
overdose.   
The proposed project seeks to expand upon existing efforts using data from VHA administrative 
records to inform strategies for clinical interventions and preventive services targeting veteran 
groups at increased risk for a fatal opioid overdose or repeat opioid overdose. 
Results from this project will specifically add to the literature in the following ways: 
1.  Increase understanding of potential differences in risk for nonfatal, repeated and fatal 
overdose. 
2. Calculate associations between an increasing number of nonfatal overdoses and risk for 
mortality or repeated events. 
3. Assess all-cause and cause-specific mortality risk among veterans with a documented 
opioid overdose.  
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1.3. Specific Aims 
Sample design 
Veterans with a documented opioid-related overdose were identified using clinical and 
administrative records from the Veterans Health Administration (VHA) Corporate Data 
Warehouse (CDW) and the VA/DoD Suicide (all-cause) Data Repository (SDR) respectively. 
The process flow of data into the CDW is shown in Figure 1 and specific ICD-9 and ICD-10 
codes used for the opioid overdose is in Appendix A and corresponding variables of interest are 
listed in Appendix B (demographic and diagnostic variables), C (codes which serve as indicators 
of social determinants of health) and D (codes used to define cause-specific mortality). 
Underlying cause of death codes used to identify cause-specific mortality can be found in 
Appendix D.   
We identified all veterans who utilized VHA services between calendar years 2011 through 2015 
by accessing patient information available from VHA’s administrative and EMR data files. 
Social Security Numbers (SSNs) were used to link to the CDW and SDR records. We extracted 
potential predictor variables including demographic information such as sex and age, procedural 
codes and diagnostic codes for the study period (2011-2015). An additional year of data was 
extracted if the index overdose occurred in the first year of the study period. For instance, if an 
individual had an opioid overdose (nonfatal or fatal) in January 2011, procedural and diagnosis 
codes were pulled from one year prior (January 2010) to index overdose.  
Inclusion/Exclusion criteria  
The cohort was restricted to veterans over 18 years or under 90 years. We excluded patients that 
did not have a follow-up visit within one year of a non-fatal overdose event. Patients with a death 
10 
 
date prior to an overdose diagnosis date were also excluded from analysis (n=145, 0.89%). Given 
that repeated overdose occurred on average more than one month after the index overdose 
(mean=36 days), patients were excluded if the first nonfatal overdose occurred in the last three 
months of the study period (October 1, 2015 to December 31, 2015). This mitigated potential 
bias among those with less than three months of documented time at risk following an overdose 
event.  
Opioid overdose cohort 
A nonfatal opioid overdose was identified using International Classification of Disease, Ninth 
Edition (ICD-9) 965.00-965.02, 965.09, E850.0-E850.2. Similarly, ICD Tenth Edition (ICD-10) 
codes were used to identify opioid overdose: X40-X44, X60-X64, X85, and Y10-Y14 and 
secondary-axis codes T40.0- T40.4, and T40.6 (Appendix A). The first opioid overdose 
documented in the compiled records was coded as the index overdose. Multiple opioid overdoses 
that occurred during an inpatient treatment stay were counted as a single overdose event, based 
on admission and discharge date. Repeat overdoses were identified among veterans with more 
than one opioid overdose recorded during the study period. A repeat overdose was defined as a 
second documented overdose that occurred a) two days after the index event with principal 
diagnosis of an overdose or b) 3 days or more after a prior overdose.  Any record of an overdose 
within one day of a previous overdose was treated as the same event.  
We identified 13,333 patients with a record of an opioid overdose between the calendar years 
2011 through 2015. Of those, there were 4,949 (37.1%) opioid overdose deaths, with a majority 
occurring on the first documented overdose (n=4,890, 98.8%). Furthermore, among these 
overdose deaths, 85.0% were unintentional (n=4,206), 6.4% were undetermined (n=315), 8.5% 
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were intentional (n=422) and 0.1% were homicide (n=6). Figure 2 depicts the specific inclusion 
and exclusion criteria for each of the specific aims.  
Predictors 
Demographic characteristics were extracted using clinical and administrative rules set by the 
VHA. For instance, sex was based on last entered value for analysis. Age was static and based on 
the patient’s age on the start of the study period, January 1, 2011.  
Date of diagnosis was based on the day of visit for the outpatient population or the date of 
discharge for the inpatient records. Potential predictors were examined one year prior to first 
documented overdose and at any point during the study period.  
All predictors were dummy coded and additional variables were created based on time of 
diagnosis, particularly in relation to index overdose. This helped describe the potential 
relationship between diagnosis and type of overdose experienced.  
This study was reviewed and approved by the Institutional Review Board at the Syracuse VA 
Medical Center, New York. 
Analysis plan 
For all aims, data management and analysis were conducted using SAS Enterprise Grid software 
(version 5.1, SAS Institute Inc.). Descriptive analysis for all variables were completed using 
cross tabulations, column percentages were reported for each outcome of interest. Alpha was set 
to 0.05 for tests unless otherwise specified. 
Specific Aim 1: Characterize differences between those with a fatal index overdose and 
those with repeated nonfatal overdoses from those with only one nonfatal index overdose. 
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Based on results from existing studies, we hypothesize that those who experienced repeated 
overdoses would have a greater number of psychiatric diagnoses and social health indicators 
than those who died on their first documented overdose [24, 68-71].  
 Bivariate analyses were conducted using chi-square test of difference among all 
sociodemographic and diagnostic variables by overdose category: fatal index overdose, repeated 
nonfatal overdoses, and only one nonfatal overdose. The primary hypotheses was tested using 
multinomial logistic regression given the polytomous outcome includes three mutually exclusive 
groups without order. As an extension of logistic regression models, this approach is flexible and 
allowed three overdose outcome levels using a generalized logit link. In addition, this approach  
provided a more direct option for interpreting the relationship between the predictors and 
outcome groups [72], is more robust to violating the assumptions of normality and does not 
assume a linear relationship between the predictors and outcome [72, 73]. Conversely, this 
method required additional comparative statements given that this method produced multiple 
odds ratios for each predictor; which could lead to issues with interpretability [72, 74]. A major 
limitation of this method may result from the independence of irrelevant alternatives (IIA) 
assumption which presumes that changing the number of outcomes (e.g. three to five levels) 
would not affect the odds of the remaining outcomes [75, 76].  Model fit for this multinomial 
logistic regression model was first assessed by using a series of logistic regression models, 
controlling for age and gender, which is known to influence overdose risk[74, 77]. Assumptions 
for multinomial logistic regression models were tested. For example, multicollinearity was 
assessed by calculating variance inflation factors (VIF). Predictors with a VIF greater than 10 
were reassessed for strength of relationship with the outcome. Of those predictors where 
collinearity was suspected, Wald chi-square tests were conducted to determine which variable 
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was more appropriate for inclusion in the final models. Weaker predictors were dropped and the 
model was rerun to only include significant predictors that were not collinear. Goodness of fit 
indices such as the Type 3 Analysis of Effects and Wald chi-square test were examined for all 
predictors with the null that all of the coefficients were equal to zero in the model[72]. 
Interactions between significant predictor variables were tested and significant interactions were 
left in the model.  Odds ratios with a 95% Confidence Interval (CI) were calculated by 
exponentiating the estimate. The adjusted odds ratio indicate the odds of experiencing a fatal 
overdose compared to those with one nonfatal overdose as well as the odds of experiencing a 
repeated nonfatal overdose compared to those with one nonfatal overdose, adjusted for all other 
predictors in the model.   
Specific Aim 2: Calculate the conditional probability of a repeat opioid overdose event 
(fatal and nonfatal) among those with record of a nonfatal opioid overdose. We expect that 
the conditional probability for repeated overdose and mortality will increase linearly with each 
overdose event.  
The frequency and conditional probability of nonfatal and fatal overdose was calculated among 
the VHA patient population with at least one overdose event during the study period (2011-
2015). We excluded overdoses that were classified as homicides or suicides. To describe the 
magnitude of repeated overdose and corresponding mortality for each overdose event, the 
conditional probability of repeated overdose and associated mortality was calculated for patients 
with at least one documented overdose in the VHA clinical records.  Conditional probability of 
an overdose was calculated by dividing the proportion of patients experiencing the event by the 
number of patients at risk for the event [78-80]. The outcome of interest was mortality at each 
overdose event (e.g., one, two, three, four, and five or more overdoses) as well as conditional 
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probability for repeated overdose event.  Conditional probabilities for overdose death and repeat 
overdose at each disease event were estimated and 95% CI were extrapolated using the normal 
approximation method. 
Specific Aim 3: Determine the 5-year cause-specific mortality rate of those who experienced 
a nonfatal opioid overdose.  We hypothesize that the mortality rate will be markedly higher 
among veterans with a prior nonfatal overdose. Further, we hypothesize that select categories of 
mortality, including suicide and substance-related mortality, will be significantly higher among 
patients with one or more previously documented overdose events. 
The number of person-years at risk of dying and relative frequencies of overall and cause-
specific causes of death were compared between those who experienced a nonfatal opioid 
overdose and a control group. Those who died from a fatal index overdose were excluded from 
the analysis. We also excluded those with a nonfatal overdose in the last three months of the 
study period. We evaluated vital status for the nonfatal overdose group and comparison group 
from the start of the study period, January 1, 2011. Continuous variables were examined to 
determine overall distribution and bivariate analysis was used to examine bivariate relationships. 
A 5% stratified random sample was pulled to compare mortality with the nonfatal overdose 
group. Pulling a stratified random sample allowed the control group to be similar in composition 
to those with a nonfatal overdose [81]. Given that VHA users are commonly older male with 
poorer health outcomes, we stratified by sex and age to reduce potential bias that may influence 
mortality among the control group [56, 58]. This method, using a stratified random sample, has 
been used in previous VHA research using clinical data due to the large sample size of the 
population [82-85]. This method allowed for controls to be pulled from a heterogeneous 
population based on specific strata, specifically sex and age [86-88]. The control group was 
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constructed to compare differences in mortality between those who experience a nonfatal opioid 
overdose to those with no documented overdose and allowed for outcome measures to be easily 
extrapolated for each stratum. We hypothesized that the mortality rate would be markedly higher 
among the nonfatal overdose group in comparison to the control group, given previous mortality 
research among a clinical population with a prior nonfatal overdose[12]/   
We evaluated mortality from the start of the study period (January 1, 2011) through the end of 
the study period (December 31, 2015). Follow-up for the study ended the day the patient died or 
the end of the study period, whichever occurred first. In addition to all-cause mortality, cause-
specific mortality was extrapolated for the following categories: external causes of death, 
suicide, homicide, accidents, substance-related deaths, drug-related deaths, alcohol-related 
deaths, infectious, viral hepatitis, human immunodeficiency virus (HIV), circulatory system, 
respiratory system, influenza, chronic respiratory disease, digestive system, cirrhosis and 
alcoholic liver disease and cancers. Specific types of cancers were categorized into the following 
groups using the International Classification of Diseases for Oncology [89]: lung and bronchus, 
liver and intrahepatic bile duct, digestive system cancers, which included esophageal, stomach, 
small intestine, colon, rectal, anal, gallbladder and pancreatic cancers, lymphoma and leukemia 
and other cancers. (See Appendix D for the full list of cause-specific mortality and 
corresponding ICD-10 codes). 
To test study hypotheses, cox proportional hazard models were used to calculate relative risk 
estimates and included demographic factors (e.g. sex and age) as covariates. Using this type of 
analysis we assumed the following: 1) the hazard ratio remained constant over time, 2) the 
independence of survival was different between each veteran in the cohort and 3) there was a 
multiplicative relationship between the predictors [90]. This semi-parametric method has been 
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used in similar research to elucidate the relationship between multiple predictors and mortality 
[12, 83, 91]. We assessed the proportional hazard assumption by comparing the observed with 
the predicted survival curves for categories of the variables in the model, curves that were 
relatively close indicated the hazard ratio remained constant over time [92]. Significant 
predictors were identified using Wald Z-tests which evaluated whether hazard ratio was equal to 
one or equivalently that the slope was equal to zero [92]. Given that a cox proportional hazard 
model is a likelihood-based method, the overall model fit was evaluated through likelihood ratio 
(LR) tests. Given the large sample size of the cohort, results from the LR test were close to Wald 
test. Interactions between two different variables were assessed to determine significance by 
examining Akaike information criteria (AIC) levels in comparison to the model without 
interaction terms. We detected violations of the hazard assumption by examining the Schoenfeld 
residuals [93].  Hazard ratios and corresponding 95% CI were extrapolated for cause-specific 
mortality.  
We identified person-years of follow-up and mortality rates per 10,000 person-years for the 
cohort. Crude death rates were calculated and adjusted mortality rates were calculated using Cox 
proportional hazard models, adjusting for age and sex.  
Mortality rates among veterans with a nonfatal overdose were compared to mortality rates in the 
US population. Standardized mortality rate ratios (SMRs) were calculated using data from the 
Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic 
Research (CDC WONDER). In order to obtain approximate estimates, age-adjusted mortality 
rates were pull for the cause specific deaths of interest among individuals between 15 and 84 
years using data from CDC WONDER. SMRs were calculated for specific causes of death by 
dividing the observed number of deaths to the expected deaths [94, 95]. 
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Limitations 
Although the VHA is the largest healthcare system in the United States, a major limitation of this 
study is that it only examines individuals who access healthcare through the VHA. Moreover, 
these study results may not generalize to the US population given the homogeneity of the veteran 
population. Moreover, veterans using VHA healthcare often experience a number of physical and 
mental health conditions compared to the general population which could result in a higher 
number of comorbidities or utilization of health care services [57]. These estimates may suffer 
from Berksonian bias, which appears when the sample is different than the general population 
leading to biased findings and is common among studies that use electronic health records [95]. 
However, the use of comparison groups and controlling for potential confounding will reduce 
potential bias that may occur.  In addition, health services could be utilized outside of the VHA 
which could alter findings, showing a lower utilization of actual health care services. The CDW 
only captures overdoses documented in the VHA system which may lead to an underestimate on 
the true number of overdoses. Another potential limitation could occur when linking datasets 
(CDW and SDR) resulting in missed overdose deaths resulting in an underestimate of total 
deaths. However, records were required to match fully on SSN and 80-90% based of the 
additional characteristics including name, date of birth and sex. 
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Table 1. Risk factors for opioid overdose  
Population characteristics 
Demographics 
♦ Male 
♦ Ages 18-45 
♦ Non-Hispanic white 
♦ Rural 
♦ Appalachian region 
Physical health conditions 
♦ Chronic pain  
♦ Liver disease 
♦ Renal disease 
♦ Chronic pulmonary disease  
♦ Cardiovascular disease 
♦ Traumatic injury 
♦ Cancer 
♦ Soft skin and tissue infections 
Mental health conditions 
♦ Mental distress 
♦ Depression 
♦ Anxiety  
♦ Previous suicide attempt 
♦ PTSD 
♦ Bipolar disorder 
Substance Use 
♦ Substance Use Disorder (SUD) 
 History of opioid dependence or abuse 
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♦ Drug use(opioids, specifically heroin) 
 High MME/day (e.g. more than 90 MME/day)  
 Severity of substance use  
♦ Co-prescribed opioids with benzodiazepines, antidepressants or antipsychotics 
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Figure 1. Process Flow of CDW 
 
Abbreviations: CDW, Corporate Data Warehouse; VHA, Veterans Health Administration   
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Figure 2. Sample Design for the Opioid Overdose Cohort 
 
Abbreviations: CDW, Corporate Data Warehouse; SDR, Suicide Data Repository 
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Chapter 2 
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2.1 Abstract 
Objective  
To compare demographic and diagnostic criteria associated with different categories of opioid 
overdoses including: fatal index (i.e. first recorded), single nonfatal, and repeat overdose 
(nonfatal).  
Methods 
Electronic health records (EHR) from the Veterans Health Administration (VHA) and death 
records from the Department of Veterans Affairs (VA)/Department of Defense (DoD) Joint 
Suicide (all-cause) Data Repository (SDR) were used to identify veterans with at least one 
documented opioid overdose between 2011 and 2015. Bivariate analyses were used to describe 
opioid overdose category and associated variables including sociodemographic characteristics, 
diagnostic factors such as chronic pain, mental health diagnosis, prior substance use, and codes 
associated with social determinants of health. Multinomial logistic regression was used to assess 
factors associated with fatal index overdose versus repeat overdose and one nonfatal overdose.   
Results 
A total of 12,848 VHA patients had at least one opioid overdose documented in VHA’s EHR 
between 2011 and 2015. Among them, 34.7% (n=4,464) died on their first documented overdose, 
20.7% (n=2,659) had at least one additional (i.e. repeat) documented overdose, and 44.6% 
(n=5,725) had only one nonfatal overdose in their medical records. Patients who were younger in 
age (18-44 OR [odds ratio] 7.19, 45-64 OR 4.78) had significantly higher odds of a fatal index 
overdose and experiencing a repeat overdose (18-44 OR 2.13, 45-64 OR 1.78). Having one or 
more chronic pain diagnoses was associated with experiencing a fatal index overdose (OR 3.96) 
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or repeat overdose (OR 1.15). A mental health or substance abuse or dependence diagnosis was 
significantly associated with experiencing a repeat overdose, (OR 1.54 and 1.25 respectively).  
Receipt of medication-assisted therapy (MAT) more than one year prior (OR 1.28) to the first 
(i.e. index) overdose was significantly associated with increased odds of a fatal overdose 
whereas receiving counseling services prior to index overdose was protective of experiencing a 
fatal index overdose.  
Conclusion 
To reduce overdose mortality and repeat morbidity, prevention efforts should target younger to 
middle aged veterans, especially those with a chronic pain diagnosis. Healthcare efforts should 
focus on treating mental health diagnoses, which are significantly associated with multiple 
overdoses. Healthcare efforts should consider integrating relapse prevention in primary care 
settings, to mitigate potential risk among patients with a history of an overdose.  
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2.2 Introduction 
Overdoses are now the leading cause of accidental death in the United States and are a growing 
concern for public health and clinical medicine. Fatal opioid overdoses have been on the rise 
since 1999 and have more than quadrupled in the United States during this time period [1-6]. In a 
similar fashion, nonfatal overdoses have also been increasing. Fatal and nonfatal overdoses are 
highest among people who inject drugs (PWID) [7-9], have an opioid use disorder (OUD) [10, 
11], or consume a high-dose of opioids [12-17].  
Prior research has found that risk factors for nonfatal overdose [13, 18-28] are similar in nature 
to those for fatal overdose [15, 17, 29-32]. The most significant risk factors for overdose include 
those related to mental health such as a diagnosis of anxiety, depression, or a history of suicide 
ideation or attempt [7, 22, 23, 28, 33-35]. Diagnostic risk factors such as chronic pain, 
respiratory disease, renal disease, and cardiovascular disease have also been associated with 
overdose risk but were not as strong as those associated with mental health diagnoses [22, 23, 33, 
34]. Research conducted among PWID suggest that homelessness and early life adversity are 
also associated with increased risk for substance abuse and overdose [30, 36, 37]. While studies 
have identified social determinants of health as significant risk factors of overdose, no studies 
have used EHRs to assess differences across categories of overdoses.  
Existing evidence suggests that the number of prior overdoses is directly related to subsequent 
risk of death from overdose[38].  Furthermore, research suggests there has been a rise in patients 
hospitalized for repeat overdose events. However, little is known about risk factors for repeat 
overdose or if they may differ from those identified with increased risk of overdose mortality 
[39].  The few studies that have examined repeat overdoses have examined intentional overdoses 
rather than those that were thought to be unintentional or of undetermined intent [40-43].   
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The purpose of this study was to identify diagnostic factors, including codes related to social 
determinants of health, associated with different opioid overdose categories including fatal index 
overdose, a single nonfatal overdose, and repeat overdose (nonfatal) using data from the one of 
the largest integrated health care systems in the U.S.   
2.3 Methods  
 
Study population 
 
We pulled a cohort of veterans who received services from the Veteran Health Administration 
(VHA) in calendar years 2011-2015. Opioid overdoses were extracted using clinical records 
from the VHA Corporate Data Warehouse (CDW) linked with death records from the VA/DoD 
Suicide Data Repository using Social Security Numbers (SSNs) [44-47]. To allow for time to 
risk, patients were excluded if their first overdose occurred in the last three months of the study 
(October 1, 2015 through December 31, 2015). Patients were also excluded from the study or if 
they did not have follow-up records within the year following a nonfatal overdose. This study 
was restricted to veterans over 18 and under 90 years of age. This cohort identified 13,333 
veterans with at least one documented opioid overdose between 2011 through 2015. After 
excluding those who died from overdoses classified as suicide (n=422) or homicide (n=6), or 
those that died on a repeat overdose (n=57), the final study cohort was 12,848.  
Opioid overdose  
Opioid overdose was defined using International Classification of Disease, Ninth Edition (ICD-
9) codes: 965.00-965.02, 965.09, E850.0-E850.2 and ICD Tenth Edition (ICD-10) codes: X40-
X44, Y10-Y14 and secondary axis codes T40.0- T40.4, and T40.6. Repeat overdose was defined 
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as either a) a second documented overdose that occurred two days after the previous overdose, 
with the overdose documented as the principal diagnosis or b) a second documented overdose 
that occurred three days or more after the previous overdose.  An overdose that occurred one day 
after a prior overdose was treated as the same event. The outcome of interest was category of 
opioid overdose: including categories for fatal index overdose, repeated nonfatal overdoses, and 
only one nonfatal overdose, which were constructed as three mutually exclusive groups.   
Predictors  
We extracted information on six domains of predictors for veterans receiving medical care from 
the VHA [46, 48]. These domains included demographic, chronic pain, mental health, substance 
abuse/dependence, MAT, and social codes, which serve as indicators of social determinants of 
health. Demographic information included age and sex of the patient. Information on race and 
ethnicity were not included due to limited availability and documented lack of reliability [49, 
50]. Age was fixed and determined based on age on the first day of the study period (January 1, 
2011). Sex was determined based on last entered value for sex in either the clinical or death 
records. 
Chronic pain 
 Chronic pain diagnoses were categorized into seven diagnostic groups: arthritis, back pain, 
migraines, headaches or tension headaches, psychogenic pain, neuropathy, and fibromyalgia. If a 
patient had a diagnosis of at least one chronic pain diagnosis, a dummy variable was created to 
identify the association between any chronic pain diagnosis prior to index overdose and type of 
subsequent overdose (i.e. any chronic pain diagnosis prior to index overdose). Classifications for 
chronic pain were guided by previous research [51].  
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Mental health 
A broad definition of mental health diagnosis was identified using ICD-9 codes 290.00 to 319.99 
or ICD-10 codes F00 to F99, excluding tobacco codes starting with 305 or F17 [52, 53]. Eight 
specific types of mental health disorders were categorized and included anxiety, depression, 
bipolar, PTSD, adjustment disorder, schizophrenia or other psychotic disorders, traumatic stress, 
and personality disorder. Two combination variables were then created to identify potential 
interactions between types of mental health diagnoses and included: 1) having either depression, 
anxiety, or PTSD, and 2) having all three mental health diagnoses (i.e. depression, anxiety, and 
PTSD). Similar to chronic pain diagnoses, a dummy variable indicating any mental health 
disorder was used to assess the relationship between mental health diagnoses and type of 
documented overdose.  
Substance abuse or dependence 
Substance abuse or dependence was measured using seven types of substance abuse or 
dependency groups including alcohol, opioid, cannabis, sedative, hypnotic, or anxiolytic, 
cocaine, other stimulant, and hallucinogens. Similar to chronic pain and mental health diagnoses, 
patients with any type of substance abuse or dependence documented in the clinical record were 
then categorized as having any type of substance abuse or dependence. Patients with more than 
one type of substance abuse or dependence were also identified as having polysubstance abuse or 
dependence to assess the potential relationship between substance abuse/dependence for multiple 
substances and type of overdose. Due to limited numbers, three types of substance 
abuse/dependency disorders were not included in tables but were included in the composite 
variable identifying any substance abuse/dependence or polysubstance abuse/dependence. Type 
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of substances explored but not specifically retained in tables include the three categories: 
cannabis, hallucinogens, and sedative, hypnotic, or anxiolytic substances.  
MAT 
Receiving MAT services was identified by a documented primary or secondary stop code 523, 
which identifies buprenorphine or methadone treatment in the clinical record [54-56]. Patients 
who received MAT prior to their index overdose were then further identified as having MAT 
more than one year prior to overdose. Exploratory analyses identified more than one year as a 
critical time point for last MAT rather than one, three or six months prior to index overdose.  
Social determinants of health 
Codes that are indicators of social determinants of health were collapsed into the following 13 
categories guided by previous literature (Torres et al., 2017; Gottlieb et al., 2016): 1) problems 
related to employment or unemployment, 2) problems related to education and literacy, 3) 
problems related to housing or economic circumstances, 4) problems related to mental or 
behavioral health, 5) problems related to upbringing, 6) problems related to social environment, 
7) problems related to primary support group, 8) problems related to psychosocial circumstances, 
9) problems related to environmental psychosocial circumstances, 10) problems related to abuse, 
11) problems related to lifestyle or lifestyle management, 12) receipt of counseling services, and 
13) receipt of counseling services for substance abuse.  
The specific diagnostic codes (ICD-9 and ICD-10) used for the predictor variables can be found 
in a Supplemental Table 1.  
This study was reviewed and approved by the Institutional Review Board at the Syracuse VA 
Medical Center, New York. 
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Analysis 
Data for this study was analyzed using SAS Enterprise Grid software (version 5.1, SAS Institute 
Inc.). Descriptive analysis for all potential predictors were completed using cross tabulations for 
all outcomes and alpha was set to 0.05 for tests unless otherwise specified. 
Bivariate analyses were conducted using chi-square test of difference, for all predictor variables 
with each overdose outcome: fatal index overdose and repeated nonfatal overdoses (Table 1). 
The reference group for all analyses was a single nonfatal opioid overdose.  
Using multinomial logistic regression, the odds ratios for repeat overdose and fatal index 
overdose were calculated for sociodemographic and diagnostic factors such as chronic pain, 
mental health diagnosis, prior substance use, and codes associated with social determinants of 
health. Multinomial regression was used to provide a more direct interpretation for the 
relationship between the predictors and category of overdose [57, 58]. As an extension of logistic 
regression, this method was selected because it is more robust to violating assumptions of 
normality and ability to compare across multiple outcome groups(57, 58).  Model fit for this 
multinomial logistic regression model was assessed by using a series of logistic regression 
models, controlling for age and gender [59, 60]. Assumptions for this method were testing by 
assessing multicollinearity among predictors with a variance inflation factor (VIF) with a critical 
value greater than ten. If evidence of collinearity was identified among predictors, Wald chi-
square tests were conducted to determine which variable was best suited for inclusion in the final 
model. Goodness of fit indices such as the Type 3 Analysis of Effects and Wald chi-square test 
were examined for all predictors [61]. Interactions between significant predictor variables were 
tested.   
37 
 
Adjusted odds ratios (OR) with 95% Confidence Intervals (CIs) were calculated for each of the 
significant predictors in the final model (Table 2). Adjusted odds ratios indicate the odds of 
experiencing a fatal overdose compared to those with one nonfatal overdose as well as the odds 
of experiencing a repeated nonfatal overdose compared to those with one nonfatal overdose, 
adjusted for all other predictors in the model.   
2.4 Results 
Our cohort consisted of 12,848 veterans with at least one documented overdose between calendar 
years 2011 to 2015. This retrospective cohort consisted primarily of men (91.5%, n=11,070) 
between the ages of 45-64 (61.3%, n=7,874). More than half had at least one chronic pain 
diagnosis (69.6%, n=8,941) the most common types of chronic pain among our cohort was 
arthritis (55.5%, n=7,129) and back pain (50.8%, n=6,521).  Among our study cohort more than 
90% had a mental health diagnosis during the study period (91.6%, n=11,768). The most 
common mental health diagnoses were depression (75.5%, n=9,703) followed by anxiety 
(60.8%, n=7,807), and PTSD (47.8%, n=6,146). In fact, 84.9% (n=10,906) of our cohort had at 
least one of those mental health diagnoses and 32.8% (n=4,208) had record of all three. A 
majority of the cohort (64.6%, n= 8,303) had at least one diagnosis associated with substance 
abuse or dependence and 40.5% (n=5,203) had more than one substance abuse or dependence 
diagnosis. Among our entire cohort, 11.1% (n=1,424) received MAT during the study period and 
among those 76.1% (n=1,084) had MAT before their index overdose. Of those who received 
MAT prior to their index overdose, 64.9% (n=704) last received MAT more than one year before 
the first overdose recorded in their VHA medical record.  
Diagnostic codes that are known as indicators of social determinants of health, or social codes, 
were present in the EHR for 92.4% of our cohort (n=11,867). The most common social code 
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documented for this cohort was receipt of counseling services, with 88.3% (n=11,338) having at 
least one counseling code on record prior to their index overdose. The other social codes which 
were frequent among this cohort were those indicating problems with housing or economic 
circumstances (39.6%, n=5,082) and problems associated with psychosocial circumstances 
(44.7%, n=5,739). (Table 1) 
Bivariate analyses showed notable differences in group compositions between those who died on 
their first overdose, those with repeat nonfatal overdoses, and those with only one nonfatal 
overdose (Table 2). There were significant differences in the age distribution for those with 
repeat overdose and fatal overdose (p<0.01). While males more often experienced a fatal index 
overdose there were no significant differences in sex distribution for those with repeated nonfatal 
overdose when compared to those with only one nonfatal overdose.  Bivariate analysis also 
suggests that those with repeated overdose events were significantly more likely to have had a 
mental health or substance abuse diagnosis when compared to those with only one nonfatal 
overdose (p<0.01). Similarly, those who died on their index overdose less frequently had any 
documented social code (p<0.01).  Those who died on their first overdose were more likely to 
have a diagnosis for chronic pain in comparison to those with one nonfatal overdose (p<0.01).  
A multivariable analysis assessing factors associated with category of overdose is provided in 
Table 3.  Males were more than 50% more likely to experience a fatal overdose when compared 
to those with a single nonfatal overdose (OR [Odds ratio] 1.57, 95% CIs [confidence interval]: 
1.34-1.83). Patients between the ages of 18-44 years were more likely to experience a fatal index 
overdose (OR 7.19, 95% CI: 5.88-8.78) or repeat overdose (OR 2.13, 95% CI 1.76-2.58) when 
compared to those who only had record of one single nonfatal overdose. Similarly, patients with 
a chronic pain diagnosis prior to their first recorded overdose were significantly more likely to 
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experience a fatal overdose (OR 3.96, 95% CI: 3.56-4.42) or repeat overdose (OR 1.15, 95% CI 
1.04-1.27). However, patients with a prior history of polysubstance abuse or dependence were 
more likely to experience a repeat overdose (OR 1.25, 95% CI: 1.13-1.38) and less likely to 
experience a fatal index overdose (OR 0.75, 95% CI: 0.68-0.82) compared to those with one 
nonfatal overdose. Patients who were last received MAT was more than one year prior to their 
index overdose were 28% more likely to experience a fatal index overdose (OR 1.28, 95% CI: 
1.05-1.55). Lastly, the odds of fatal index overdose were significantly lower among those 
receiving counseling services prior to their first known overdose (OR 0.35, 95% CI: 0.30-0.40).  
2.5 Discussion 
Overall, these findings suggest that men were more likely to experience a fatal index overdose 
and younger and middle-aged patients (aged 18-64 years) were more likely to experience either a 
fatal index overdose or repeat overdose; results that are similar to previously identified 
associations [4, 5, 15]. These findings suggest the need for targeted overdose prevention 
programs targeting younger to middle aged men.  
Similarly, those who experienced either a fatal index or repeat overdose were also more likely to 
have a chronic pain diagnosis prior to their index event, underscoring the need for integrated 
health care, which is consistent with other research findings [22, 23] and supports the need for 
continued efforts to identify and support alternative approaches to management of chronic pain 
[62-64]. While the CDC has developed Chronic Pain Guidelines, these findings suggest the need 
to amplify risk management of chronic pain patients by additional education or co-prescription 
of naloxone [65]. 
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Interestingly, patients with a mental health diagnosis or polysubstance abuse/dependence were 
more likely to experience a repeat overdose and less likely to experience a fatal index overdose 
when compared to those with a single nonfatal overdose. Although there is evidence that mental 
health diagnoses are more prevalent among those who experience an overdose, this is the first 
study to identify a difference in magnitude in the associations between mental health diagnosis 
and category of opioid overdoses [33, 66]. This is an interesting and important finding 
considering previous reports that suggests repeat overdose trends are increasing [39]. Healthcare 
systems should be ready for the potential for a higher number of patients and consider integrating 
mental health services with emergency care and substance abuse treatment.  
In addition to one or more mental health diagnoses, receiving counseling services prior to the 
index overdose was protective against experiencing a fatal index overdose. Conversely, those 
who received their last MAT services a year or more ago were more likely to experience a fatal 
index event during our study period. These findings highlight the need for healthcare systems to 
treat OUD using a disease model approach and suggest the need for relapse prevention in 
primary care settings [67]. Substance use disorder (SUD) is a chronic disease with relapse rates 
comparable to other common health conditions, such as hypertension [68-72]. Future clinical 
efforts should be supported to identify and address SUD in primary care settings similar to other 
chronic diseases. 
Strengths and limitations 
To the best of our knowledge, this is the first study to compare risk factors by category of opioid 
overdose history. This study used data from one of the largest integrated healthcare systems in 
the United States. However, this study is not without limitations. The information collected on 
category of overdose which relies on clinical recording and may not be present if an individual 
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does not seek medical care for an overdose or a clinician does not document the event. 
Therefore, the true number of overdoses may be underestimated. This analysis was conducted 
among the veteran population and results from this study may not be generalizable to the general 
population. The associations with measures of social determinants of health explored in this 
study may be biased given that there is evidence that they are more likely to be entered by mental 
health professionals, particularly psychiatrists, when compared to other medical specialties [73, 
74]. The decision to omit patients who die on a repeat overdose could systematically exclude 
characteristics associated with death after multiple overdoses. However, the small number of 
cases prevent inclusion as a second category and characteristics among these patients may be 
different when compared to those who died on their index overdose. Future research should 
consider characteristics associated with mortality among those with multiple overdose events.  
It is important to note that various public health interventions have been implemented to reduce 
overdose among people at highest risk [16, 75-78]. These efforts have largely been focused on 
reducing the excess supply of opioids through education programs, surveillance systems 
designed to reduce the availability of prescription opioids (e.g. prescription drug monitoring 
programs), and prevention of overdose-related mortality through broad availability of naloxone. 
In general, nonfatal and fatal overdoses appear to be impacting younger and middle aged 
veterans, suggesting that primary prevention efforts in the future may want to tailor the programs 
to this audience. Chronic pain, psychiatric diagnoses, and contextual factors appear differentially 
associated with fatal index overdose in comparison to those with repeated nonfatal overdoses.  
These findings underscore the need for integrated healthcare to address mental health and 
chronic pain among patients at risk for an opioid overdose.   
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Table 1. Demographic and diagnostic characteristics of veterans with a documented opioid 
overdose, 2011-2015 
      n (n=12,848) % 
Demographic     
Sex         
  Female 1,098 8.55 
  Male 11,750 91.45 
      
 
Age (years)       
  18-44 3,879 30.19 
  45-64 7,874 61.29 
  65+ 1,095 8.52 
     
 
Type of pain diagnosis prior to index OD        
Any chronic pain diagnosis        
  No 3,907 30.41 
  Yes 8,941 69.59 
        
Arthritis         
  No 5,719 44.51 
  Yes 7,129 55.49 
        
Back pain        
  No 6,327 49.25 
  Yes 6,521 50.75 
        
Migraines        
  No 11,978 93.23 
  Yes 870 6.77 
        
Headaches or tension headaches       
  No 11,075 86.20 
  Yes 1,773 13.80 
        
Psychogenic         
  No 12,586 97.96 
  Yes 262 2.04 
        
Neuropathy        
  No 11,804 91.87 
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  Yes 1,044 8.13 
      
Fibromyalgia         
  No 12,187 94.86 
  Yes 661 5.14 
      
Mental health diagnosis       
Any mental health diagnosis     
  No 1,080 8.41 
  Yes 11,768 91.59 
       
 
Anxiety          
  No 5,041 39.24 
  Yes 7,807 60.76 
       
 
Depressive disorder      
  No 3,145 24.48 
  Yes 9,703 75.52 
       
 
Bipolar          
  No 9,764 76.00 
  Yes 3,084 24.00 
       
 
PTSD          
  No 6,702 52.16 
  Yes 6,146 47.84 
       
 
Adjustment disorder      
  No 9,333 72.64 
  Yes 3,515 27.36 
       
 
Schizophrenia or other psychotic disorder      
  No 10,334 80.43 
  Yes 2,514 19.57 
       
 
Traumatic stress        
  No 11,071 86.17 
  Yes 1,777 13.83 
       
 
Personality disorder     
  No 10,090 78.53 
  Yes 2,758 21.47 
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Either depression, anxiety, or PTSD diagnosis     
  No 1,942 15.12 
  Yes 10,906 84.88 
       
 
All three diagnosis (depression, anxiety, & PTSD)      
  No 8,640 67.25 
  Yes 4,208 32.75 
       
 
Substance abuse/dependence      
Any substance abuse/dependence diagnosis       
  No 4,545 35.38 
  Yes 8,303 64.62 
       
 
Polysubstance abuse/dependence diagnosis  a     
  No 7,645 59.50 
  Yes 5,203 40.50 
       
 
Alcohol abuse or dependence diagnosis       
  No 6,968 54.23 
  Yes 5,880 45.77 
       
 
Opioid abuse or dependence diagnosis       
  No 7,137 55.55 
  Yes 5,711 44.45 
       
 
Cocaine abuse or dependence diagnosis       
  No 10,052 78.24 
  Yes 2,796 21.76 
       
 
Other stimulant abuse or dependence diagnosis       
  No 11,873 92.41 
  Yes 975 7.59 
       
 
Medication-Assisted Treatment     
Ever had MAT       
  No 11,424 88.92 
  Yes 1,424 11.08 
       
 
MAT before index overdose     
  No 11,764 91.56 
  Yes 1,084 8.44 
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MAT more than 1 year before index OD     
  No 12,144 94.52 
  Yes 704 5.48 
       
 
Social determinants of health (SDoH)      
Any code related to SDoH     
  No 981 7.64 
  Yes 11,867 92.36 
       
 
Counseling services       
  No 1,510 11.75 
  Yes 11,338 88.25 
       
 
Problems related to housing and economic circumstances       
  No 7,766 60.45 
  Yes 5,082 39.55 
       
 
Problems related to education and literacy       
  No 11,689 90.98 
  Yes 1,159 9.02 
       
 
Problems related to environmental psychosocial circumstances      
  No 7,109 55.33 
  Yes 5,739 44.67 
       
 
Problems related to mental and behavioral       
  No 12,690 98.77 
  Yes 158 1.23 
       
 
Problems related to social environment       
  No 9,686 75.39 
  Yes 3,162 24.61 
       
 
Other problems related to primary support group       
  No 11,794 91.80 
  Yes 1,054 8.20 
       
 
Problems related to upbringing       
  No 12,620 98.23 
  Yes 228 1.77 
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Abbreviations: OD, overdose; PTSD, post-traumatic stress disorder, SDoH, social determinants of health; MAT, 
medication-assisted treatment 
a. Polysubstance use or dependence refers to a patient having a diagnosis for more than one substance during the 
study period (2011-2105). 
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Table 2. Bivariate analysis of demographic and diagnostic characteristics by type of opioid 
overdose among veterans, 2011-2015 a 
      
No repeat OD 
(n=5,725) 
Repeat non-fatal OD 
( n=2,659) 
Fatal index OD 
 ( n=4,464) 
      
      n % n % p  n % p  
Demographic                 
Sex                     
  Female 528 9.22 261 9.82   309 6.92   
  Male 5,197 90.78 2,398 90.18   4,155 93.08   
           0.39    <0.01 
Age                   
  18-44 years 1,488 25.99 853 32.08   1,538 34.45   
  45-64 years 3,494 61.03 1,630 61.30   2,750 61.60   
  65+ years 743 12.98 176 6.62   176 3.94   
          <0.01    <0.01 
Type of pain diagnosis prior to index OD               
Any chronic pain diagnosis                
  No 2,112 36.89 900 33.85   895 20.05   
  Yes 3,613 63.11 1,759 66.15   3,569 79.95   
            <0.01    <0.01 
Arthritis                     
  No 2,915 50.92 1,269 47.72   1,535 34.39   
  Yes 2,810 49.08 1,390 52.28   2,929 65.61   
            <0.01    <0.01 
Back pain                    
  No 3,226 56.35 1,440 54.16   1,661 37.21   
  Yes 2,499 43.65 1,219 45.84   2,803 62.79   
            0.06    <0.01 
Migraines                    
  No 5,390 94.15 2,489 93.61   4,099 91.82   
  Yes 335 5.85 170 6.39   365 8.18   
            0.33    <0.01 
Headaches or tension headaches                
  No 5,042 88.07 2,323 87.36   3,710 83.11   
  Yes 683 11.93 336 12.64   754 16.89   
            0.36    <0.01 
Psychogenic                     
  No 5,647 98.64 2,627 98.80   4,312 96.59   
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  Yes 78 1.36 32 1.20   152 3.41   
            0.55    <0.01 
Neuropathy                
  No 5,207 90.95 2,444 91.91   4,153 93.03   
  Yes 518 9.05 215 8.09   311 6.97   
          0.15    <0.01 
Fibromyalgia                
  No 5,483 95.77 2,526 95.00   4,178 93.59   
  Yes 242 4.23 133 5.00   286 6.41   
          0.11    <0.01 
Mental health diagnosis                 
Any mental health diagnosis                 
  No 261 4.56 61 2.29   758 16.98   
  Yes 5,464 95.44 2,598 97.71   3,706 83.02   
            <0.01    <0.01 
Anxiety                     
  No 1,920 33.54 772 29.03   2,349 52.62   
  Yes 3,805 66.46 1,887 70.97   2,115 47.38   
            <0.01    <0.01 
Depressive disorder                 
  No 1,005 17.55 397 14.93   1,743 39.05   
  Yes 4,720 82.45 2,262 85.07   2,721 60.95   
            <0.01    <0.01 
Bipolar                     
  No 4,232 73.92 1,900 71.46   3,632 81.36   
  Yes 1,493 26.08 759 28.54   832 18.64   
            0.02    <0.01 
PTSD                     
  No 2,760 48.21 1,502 56.49   2,800 62.72   
  Yes 2,965 51.79 1,157 43.51   1,664 37.28   
            <0.01    <0.01 
Adjustment disorder                 
  No 3,930 68.65 1,765 66.38   3,638 81.50   
  Yes 1,795 31.35 894 33.62   826 18.50   
            0.04    <0.01 
Schizophrenia or other psychotic disorder                
  No 4,277 74.71 2,079 78.19   3,978 89.11   
  Yes 1,448 25.29 580 21.81   486 10.89   
            <0.01    <0.01 
Traumatic stress                   
  No 4,778 83.46 2,213 83.23   4,080 91.40   
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  Yes 947 16.54 446 16.77   384 8.60   
            0.80    <0.01 
Personality disorder                 
  No 4,316 75.39 1,934 72.73   3,840 86.02   
  Yes 1,409 24.61 725 27.27   624 13.98   
            <0.01    <0.01 
Either depression, anxiety, or PTSD diagnosis               
  No 575 10.04 197 7.41   1,170 26.21   
  Yes 5,150 89.96 2,462 92.59   3,294 73.79   
                 <0.01 
All three diagnosis (depression, anxiety, & PTSD)              
  No 3,573 62.41 1,512 56.86   3,555 79.64   
  Yes 2,152 37.59 1,147 43.14   909 20.36   
            <0.01    <0.01 
Substance abuse/dependence                  
Any substance abuse/dependence diagnosis                 
  No 1,897 33.14 661 24.86   1,977 44.29   
  Yes 3,828 66.86 1,998 75.14   2,487 55.71   
            <0.01    <0.01 
Polysubstance abuse/dependence diagnosis b               
  No 3,337 58.29 1,323 49.76   2,985 66.87   
  Yes 2,388 41.71 1,336 50.24   1,479 33.13   
            <0.01    <0.01 
Alcohol abuse or dependence diagnosis                 
  No 2,993 52.28 1,239 46.60   2,736 61.29   
  Yes 2,732 47.72 1,420 53.40   1,728 38.71   
            <0.01    <0.01 
Opioid abuse or dependence diagnosis                 
  No 3,070 53.62 1,189 44.72   2,878 64.47   
  Yes 2,655 46.38 1,470 55.28   1,586 35.53   
            <0.01    <0.01 
Cocaine abuse or dependence diagnosis                  
  No 4,509 78.76 1,945 73.15   3,598 80.60   
  Yes 1,216 21.24 714 26.85   866 19.40   
            <0.01    0.02 
Other stimulant abuse or dependence diagnosis               
  No 5,225 91.27 2,371 89.17   4,277 95.81   
  Yes 500 8.73 288 10.83   187 4.19   
            <0.01    <0.01 
Medication-Assisted Treatment                 
Ever had MAT                   
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  No 5,097 89.03 2,264 85.14   4,063 91.02   
  Yes 628 10.97 395 14.86   401 8.98   
            <0.01    <0.01 
MAT before index OD                 
  No 5,297 92.52 2,398 90.18   4,069 91.15   
  Yes 428 7.48 261 9.82   395 8.85   
            <0.01    0.01 
MAT more than 1 year before index OD               
  No 5,433 94.90 2,476 93.12   4,235 94.87   
  Yes 292 5.10 183 6.88   229 5.13   
            <0.01    0.95 
Social determinants of health                  
Any code for social determinant of health               
  No 237 4.14 120 4.51   624 13.98   
  Yes 5,488 95.86 2,539 95.49   3,840 86.02   
            0.43    <0.01 
Counseling services                   
  No 450 7.86 200 7.52   860 19.27   
  Yes 5,275 92.14 2,459 92.48   3,604 80.73   
            0.59    <0.01 
Problems related to housing and economic circumstances               
  No 3,482 60.82 1,535 57.73   2,749 61.58   
  Yes 2,243 39.18 1,124 42.27   1,715 38.42   
            <0.01    0.43 
Problems related to education and literacy                  
  No 5,143 89.83 2,398 90.18   4,148 92.92   
  Yes 582 10.17 261 9.82   316 7.08   
            0.25    <0.01 
Problems related to environmental psychosocial circumstances              
  No 2,901 50.67 1,396 52.50   2,812 62.99   
  Yes 2,824 49.33 1,263 47.50   1,652 37.01   
            0.12    <0.01 
Problems related to mental and behavioral                 
  No 5,653 98.74 2,618 98.46   4,419 98.99   
  Yes 72 1.26 41 1.54   45 1.01   
            0.29    0.24 
Problems related to social environment                  
  No 4,111 71.81 1,975 74.28   3,600 80.65   
  Yes 1,614 28.19 684 25.72   864 19.35   
            0.02    <0.01 
Other problems related to primary support group                
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  No 5,193 90.71 2,427 91.27   4,174 93.50   
  Yes 532 9.29 232 8.73   290 6.50   
            0.40    <0.01 
Problems related to upbringing                   
  No 5,603 97.87 2,611 98.19   4,406 98.70   
  Yes 122 2.13 48 1.81   58 1.30   
            0.33    <0.01 
Abbreviations: OD, overdose; PTSD, Post-Traumatic Stress Disorder; MAT, Medication-Assisted Treatment 
a. Bivariate analysis examined patient characteristics that were different among those with a repeated 
overdose and fatal index overdose in comparison to those with only non-fatal overdose.  
b. Polysubstance use or dependence refers to a patient having a diagnosis for more than one substance 
during the study period (2011-2105).  
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Table 3. Multinomial regression analysis of factors associated with type of opioid overdoses 
among Veterans, 2011-2015 
      Repeat OD (n=2,659) Fatal index OD (n=4,464) 
      
      OR 95% CI OR 95% CI 
Sex             
Male   0.98 (0.83-1.14) 1.57 (1.34-1.83) 
Female   1.00 Ref 1.00 Ref 
Age (years)           
  18-44 2.13 (1.76-2.58) 7.19 (5.88-8.78) 
  45-64 1.78 (1.49-2.13) 4.78 (3.95-5.78) 
  65+ 1.00 Ref 1.00 Ref 
Chronic pain diagnosis          
Yes   1.15 (1.04-1.27) 3.96 (3.56-4.42) 
No   1.00 Ref 1.00 Ref 
Mental health diagnosis          
Yes   1.54 (1.15-2.07) 0.18 (0.15-0.22) 
No   1.00 Ref 1.00 Ref 
Polysubstance abuse or dependence a         
Yes   1.25 (1.13-1.38) 0.75 (0.68-0.82) 
No   1.00 Ref 1.00 Ref 
MAT more than 1 year prior to index OD          
Yes   1.18 (0.97-1.44) 1.28 (1.05-1.55) 
No   1.00 Ref 1.00 Ref 
Received counseling services           
Yes   0.93 (0.78-1.12) 0.35 (0.30-0.40) 
No     1.00 Ref 1.00 Ref 
Abbreviations: OR, Odds Ratio; CI, Confidence Interval; OD, overdose; MAT, Medication-Assisted Treatment 
a. Polysubstance use or dependence refers to a patient having a diagnosis for more than one substance during 
the study period (2011-2105). 
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Supplement Table 1. Corresponding ICD-9 and ICD-10 Codes for Variables 
Characteristic ICD-9 and ICD-10 code 
Psychosocial & related mental health diagnoses 
Any mental health diagnosis ICD-9: 290.00 to 319.99, excluding tobacco codes starting with 305  ICD-10: F00 to F99, excluding tobacco codes starting with F17 
Anxiety ICD-9: 300 ICD-10: F40, F41 
Depression ICD-9: 296.2, 296.3, 300.4, 311  ICD-10: F32, F33, F34.1 
Bipolar ICD-9: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8 ICD-10: F31 
PTSD ICD-9: 309.81 ICD-10: F43.1 
Adjustment disorder ICD-9: 309.0, 309.24, 309.28, 309.3, 309.4, 309.9  ICD-10: F43.20- F43.25 
Schizophrenia or other psychotic 
disorders 
ICD-9: 295.90, 295.40, 295.70, 297.1, 297.3, 298.8, 293.81, 293.82, 
298.9  
ICD-10: F20.9, F20.81, F25.0, F25.1, F22, F24, F23, F06.2, F06.0, F29) 
Traumatic stress ICD-9: 308.9, 309.89, 309.9 ICD-10: F43.0 F43.8, F43.9 
Personality disorder 
ICD-9: 301.83, 301.7, 301.81, 301.50, 301.4, 301.82, 301.6, 301.0, 
301.20, 310.1 301.9  
ICD-10: F60, F61 
Opioid abuse/dependence ICD-9 codes: 304.0, 304.7, 305.5 ICD-10 codes: F11 
Alcohol abuse/dependence  ICD-9: 303, 305.0  
ICD-10: F10 
Cannabis abuse/dependence  ICD-9: 304.3, 305.2 
ICD-10: F12 
Sedative, hypnotics, or anxiolytic 
abuse/dependence 
ICD-9: 304.1, 305.4 
ICD-10: F13 
Cocaine abuse/dependence ICD-9: 304.2, 305.6 
ICD-10: F14 
Other stimulant abuse/dependence ICD-9: 304.4, 305.7 
ICD-10: F15 
Hallucinogen abuse/dependence  ICD-9: 304.5, 305.3  
ICD-10: F16 
Any substance abuse/dependence  
Any diagnosis for substance abuse/dependence  
Polysubstance abuse/dependence 
At least two combinations of the substance abuse/dependence diagnosis 
TBI 
ICD-9: 800.0-801.9, 803.0-804.9, 850.0-854.1, 950.1-950.3, 995.55, 
959.01  
ICD-10: S02.0, S02.1, S02.8, S02.91, S04.02, S04.03, S04.04, S06, 
S07.1, T74.4  
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Medication-Assisted Treatment (MAT) 
Record of MAT Using stop code 523 (primary or secondary stop code) to identify MAT 
services 
Chronic pain before index OD 
Back pain ICD-9: 720.0-724.9 
ICD-10: M45.9- M46.1, M46.90, M47.812, M47.12, M47.814, M47.817, 
M48.20, M48.10, M48.30, M48.9, M50.20, M51.9, M50.30, M51.34-
M51.37, M48.02, M54.2, M53.0, M53.1, M54.12, M54.13,M43.6, 
M54.02, M67.88, M53.82, M54.6, M54.5, M54.30, M54.14-M54.17, 
M54.89-M54.9, M43.27, M43.28, M53.2X7, M53.3, M54.08, M43.8X9, 
M53.9 
Arthritis  ICD-9: 710.0-739.9, excluding back pain codes 
ICD-10: M00-M02, M36.2, M36.3, M12, M35.3, M15, M16-M19, M05-
M08, M1A, M10-M14 
Migraines ICD-9: 346.0-346.9 
ICD-10:G43.0, G43.1, G43.4, G43.5, G43.6, G43.7, G43.8, G43.9, 
G43.A, G43.B, G43.C, G43.D 
Headaches or tension headaches ICD-9: 784.0 and 307.81 
ICD-10: G44.1, R51, G44.209 
Psychogenic ICD-9: 307.80 and 307.89 
ICD-10: F45.41, F45.42 
Neuropathy ICD-9: 355.0, 355.9, 356.0, 357.2, 357.9 
ICD-10:G57.00, G58.9, G60, E08.42, E09.42, E10.42, E11.42, E13.42, 
G61.9 
Fibromyalgia ICD-9: 729.1 
ICD-10: M60.9, M79.1, M79.7 
Any chronic pain diagnosis Any of the diagnoses for chronic pain  
Social determinants of health (SDoH) codes prior to index OD 
Problems related to housing and 
economic circumstances 
ICD-9:  V60.0, V60.1, V60.89, V60.6, V60.2, V60.9 
ICD-10: Z59 (Z59.0-Z59.9) 
Problems related to support group, 
including family and relationships 
ICD-9:  V61.0, V61.05, V61.8, V61.01, V61.06, V61.07, V61.08, 
V62.82, V61.03, V61.49, V61.02, V61.41, V61.3, V61.04, V61.09, 
V61.8, V61.9 
ICD-10: Z63 (Z63.0-Z63.9) 
Problems related to social 
environment 
ICD-9:  V60.3, V62.4, V62.89 
ICD-10: Z60.0, Z60.2, Z60.3, Z60.4, Z60.5, Z60.8, Z60.9 
Problems related to upbringing ICD-9:  V61.29, V61.8, V60.81 
ICD-10: Z62.0, Z62.1, Z62.2, Z62.3, Z62.6, Z62.8 
Problems related to environmental 
psychosocial circumstances 
ICD-9:  V62.5, V62.89, V62.81, V62.9 
ICD-10: Z65.0, Z65.1, Z65.2, Z65.3, Z65.4, Z65.5, Z65.8, Z65.9 
Problems related to abuse  ICD-9:  V61.21, V61.22, V62.83, V61.11, V61.12, V65.49 
ICD-10: Z69.0, Z69.01, Z69.02, Z69.1, Z69.8 
Counseling services ICD-9:  V65.49, V61.2, V61.1, V65.40, V65.9 
ICD-10: Z71.81, Z71.89, Z71.9 
Other problems related to mental 
and behavior 
ICD-9:  V40.0, V40.2, V40.3, V40.31, V40.39, V40.9 
ICD-10: F48.9, F69 
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Any SDoH Any of the above SDoH codes captured before index OD 
Abbreviations: ICD, International Classification of Disease; ICD-9, International Classification of Disease, Ninth 
Edition; ICD-10, International Classification of Disease, Tenth Edition; PTSD, Post-traumatic stress disorder; TBI, 
Traumatic Brian Injury; MAT, Medication-Assisted Treatment; OD, overdose; SDoH, social determinant of health 
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Chapter 3 
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3.1 Abstract 
Objective 
To determine the conditional probability of repeat overdose among patients with one or more 
prior overdose events and corresponding probability of overdose mortality.  
Methods 
Clinical records were extracted between 2011 through 2015 for veterans receiving medical care 
from the Veterans Health Administration (VHA). Vital status was determined by linking data 
from the patient’s medical record to information contained in the VA/DoD Joint Suicide (all-
cause) Data Repository (SDR). Conditional probability of repeated overdose and mortality was 
calculated among patients with at least one recorded overdose.  
Results 
There were 12,905 veterans with at least one opioid overdose between 2011 and 2015. Among 
this study sample, one fifth (n=2,716) had a repeated opioid overdose during the study period. 
The conditional probability for repeated overdose more than doubled for each overdose event 
from 21.1% for a second overdose to 43.2% for five or more overdoses. Mortality was highest 
for the first documented overdose (34.6%).  
Conclusion 
Overdose prevention efforts should be expanded and include primary prevention efforts targeting 
those at highest risk for overdose morbidity and mortality; including those not currently 
receiving treatment for opioid abuse or misuse. Additional research is needed to identify risk 
factors for repeated overdose and corresponding mortality to curtail the current opioid crisis.  
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3.2 Introduction 
Opioid overdoses are a growing public health concern. In the United States, the opioid overdose 
mortality rate increased by 413% since 1999, from a rate of 2.9 to 14.9 per 100,000 [1-5]. In 
addition to fatal overdoses, nonfatal overdoses resulting in either inpatient admission or 
emergency department visits have been substantially increasing in the past decade [6, 7]. Despite 
the observed rise in overdoses, little is known about the risk of repeated overdose events and 
corresponding mortality. Prior research suggests that a history of overdose and psychiatric 
diagnoses are risk factors for repeat overdose among persons who engage in self-harm behavior 
or inject drugs [8-11]. However little is understood regarding the risks associated with repeat 
overdose among patients in a general patient population.  
The overall objective of this study was to calculate the conditional probability of a repeat opioid 
overdose event and mortality for each overdose event among veterans who use VHA services. 
This research is important because it will elucidate the number of documented opioid overdose 
events a patient experiences and will identify the overdose event associated with highest 
overdose mortality using data from the largest integrated health care system in the U.S.. 
3.3 Methods 
Sample design 
This study cohort included 13,333 veterans with at least one documented opioid overdose 
between January 1, 2011 and December 31, 2015. Opioid overdoses were extracted using clinical 
records from the VHA Corporate Data Warehouse (CDW) [12].  CDW records were linked with 
mortality records from the VA/DoD Suicide (all-cause) Data Repository using Social Security 
Numbers (SSNs) [13, 14]. Vital status was determined for these patients through the 2015 
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calendar year. Sex and age were extracted from clinical and mortality files. Age was static and 
determined on the start of the study period (January 1, 2011). 
Opioid overdose  
An opioid overdose was identified using International Classification of Disease, Ninth Edition 
(ICD-9) codes: 965.00-965.02, 965.09, E850.0-E850.2 and ICD Tenth Edition (ICD-10) codes: 
X40-X44, Y10-Y14 and secondary axis codes T40.0- T40.4, and T40.6. The first opioid 
overdose documented in the clinical records between calendar years 2011 to 2015 was used as 
the index overdose. Repeat overdose was defined as a second documented overdose that either 
occurred two days after the previous overdose with the overdose documented as the principal 
diagnosis or a second documented overdose that occurred or more than three days after the prior 
overdose.  
The study sample was restricted to veterans between 18 and 90 years old. To allow time for 
repeated events, we excluded patients that had no follow-up visits within one year of the first 
overdose event or had their first overdose in the last three months of the study period (October 1, 
2015-December 1, 2015). For this study, we excluded patients with an opioid overdose death that 
was classified as intentional or homicide, yielding a total of 12,905 patients.  
This study was reviewed and approved by the Institutional Review Board at the Syracuse VA 
Medical Center, New York. 
Analysis plan 
The frequency and conditional probability of nonfatal and fatal overdose were estimated among 
the total VHA patient population with at least one overdose event during the study period (2011-
2015). Conditional probability of an overdose was calculated by dividing the proportion of 
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patients experiencing the event by the number of patients at risk for the event [15-17]. The 
conditional probability of interest was mortality at each overdose event for each disease event 
(e.g., one, two, three, four or more overdoses) as well as conditional probability for repeated 
nonfatal overdose event. Conditional probabilities for overdose death and repeat overdose at 
each disease event were estimated and 95% confidence intervals were extrapolated using the 
normal approximation method.  
3.4 Results 
There were 12,905 veterans with at least one overdose event documented in VHA’s electronic 
medical record (EMR). The conditional probability of repeated overdose increased directly with 
the number of overdose events. The conditional probability for repeated overdoses more than 
doubled from 21.1% following one nonfatal overdose event to 43.2% for experiencing four or 
more overdoses (Table 1). In total, 4,521 veterans experienced a fatal overdose; accounting for 
35.0% of the VHA patients with a recorded overdose. The proportion of deaths was highest for 
the first documented overdose (98.8%) compared to subsequent fatal overdose events (Figure 1). 
3.5 Discussion 
More than twenty percent of patients with a documented opioid overdose had at least one 
repeated overdose documented in the records during the five year study period (January 1, 2011- 
December 31, 2015).  With every overdose event, the probability of experiencing an additional 
overdose continued to increase but the probability of overdose death was consistently low. 
Patients were 17 times more likely to die from an opioid overdose on their first documented 
overdose event during the study period. Given that overdose mortality was highest among 
patients with no prior overdose during this time period, prevention efforts should be focused on 
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amplifying resources to those without documented overdose risk. Additional research is needed 
to understand the risks associated with repeat overdose to inform future clinical and public health 
interventions directed at those with history of multiple overdoses. 
Although overdose was obtained from one of the nation’s largest healthcare records, this study 
has several limitations. Findings relied on patients seeking medical care for an overdose which 
could underestimate the true number of overdoses an individual experienced. Data collected was 
among the veteran population so results may not be generalizable to the general population or 
users of other health systems. Additional studies are needed to understand if these results hold 
true in other healthcare populations. Due to the limited scope of this analysis additional factors 
may be present which in turn increase the risk of repeat overdose and associated fatality. Finally 
this project only included overdoses that were documented by VHA clinician during the study 
period. It is possible that previous overdoses outside of the study period or those were otherwise 
undocumented were not captured. Inclusion of these may change distribution across categories or 
estimated conditional probabilities.  
These results suggest the need for additional research, specifically examining potential unique 
risk factors for experiencing a repeat overdose. Given the rates of repeat overdose increased in a 
linear fashion, these findings suggest that healthcare systems should be ready for an influx in 
patients with opioid overdoses.  Furthermore, these findings underscore the urgent need to 
expand overdose prevention efforts, such as naloxone distribution to patients with no history of 
an overdose.   
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Table 1. Repeated opioid overdoses and subsequent mortality among patients between 2011-2015  
  
No. of overdoses  
No. of 
fatal 
OD 
No. of 
OD a 
Conditional 
probability 
of repeated 
OD 
95% CI of 
repeated event a 
Probability 
of overdose 
mortality 
95% CI of 
mortality a 
One overdose 4,464 12,905   34.59 (33.77-35.42) 
Two overdoses 30 2,716 21.05 (20.35-21.76) 1.10 (0.76-1.59) 
Three overdoses 15 954 35.13 (33.33-36.96) 1.57 (0.92-2.64) 
Four overdoses 8 396 41.51 (38.37-44.72) 2.02 (0.94-4.10) 
More than 5 overdoses 4 171 43.18 (38.27-48.23) 2.34 (0.75-6.26) 
       
Abbreviations: OD, overdose; CI, confidence interval; No., Number 
a. Number of total overdoses indicate the total number of overdoses a patient experienced during the study period. 
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Figure 1. Mortality for each opioid overdose event recorded, 2011-2015 
 
Abbreviations: CI, Confidence Interval 
 
 
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
40.00
1 overdose 2 overdoses 3 overdoses 4 overdoses 5+ overdoses
Pe
rc
en
t (
%
) o
f m
or
ta
lit
y 
fo
r e
ac
h 
do
cu
m
en
te
d 
ov
er
do
se
 ev
en
t
Opioid overdose mortality for each recorded opioid overdose, 2011-2015
Probability of overdose mortality with 95% CI
70 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
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4.1 Abstract 
Objective 
To identify cause-specific mortality rates and calculate standardized mortality rate ratios (SMRs) 
among veterans with a prior nonfatal opioid overdose.  
Methods 
We followed 8,370 veterans who received medical care for a nonfatal opioid overdose between 
January 1, 2011 and December 31, 2015 or date of death, whichever occurred first. Mortality 
records were extracted from the Department of Veteran Affairs (VA)/Department of Defense 
(DoD) Joint Suicide (all-cause) Data Repository (SDR) and linked to clinical records from the 
Veterans Health Administration (VHA).  We compared the mortality rates among those with a 
nonfatal opioid overdose to a 5% stratified random sample of patients accessing services during 
the same time period (n=325,073). SMRs were calculated using age-adjusted cause-specific 
mortality rates for the general U.S. population obtained from the Centers for Disease Control and 
Prevention’s Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER).  
Results 
The study cohort included 8,370 veterans with history of a nonfatal opioid overdose resulting in 
a total of 39,207 person-years of follow-up. The crude mortality for veterans with a history of a 
nonfatal overdose was 370.6 per 10,000 person years and SMR was 26.2 (95% CI [confidence 
interval]: 24.6-27.6). The most common causes of death among these veterans of interest were 
deaths associated with the circulatory system (26.7%), cancer (19.3%), deaths associated with 
the respiratory system (13.1%) and drug-related deaths (11.6%). Those with a prior nonfatal 
overdose had a higher risk of substance-related mortality (aHR [adjusted Hazard Ratio] 5.0, 95% 
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CI 4.4-5.8), including a higher risk of death from drugs (aHR 6.9; 95% CI 5.8-8.1) and alcohol 
(aHR 2.7, 95% CI 2.1-3.6). For cause-specific mortalities assessed between veterans and the 
general U.S. population, SMRs were also highest for deaths associated with substances (114.0, 
95% CI 98.8-128.7), including drugs (139.3, 95% CI 118.6-160.7) and alcohol (72.7, 95% CI 
53.5-92.4). As expected, SMRs for viral hepatitis (107.4, 95% CI 65.5-152.7) and liver cancers 
(68.2, 95% CI 47.9-88.7) were substantially higher when compared to rates for these outcomes in 
the U.S. general population. Other cause-specific diseases that were elevated included suicide 
(29.0, 95% CI 20.0-38.2) and HIV (34.9, 95% CI 10.7-58.9). Deaths related to the digestive 
system (45.2, 95% CI 36.7-53.7) and respiratory system (35.4, 30.4-40.4) were also markedly 
higher than the general population.  
Conclusion 
Veterans with a prior nonfatal overdose experienced a substantially higher mortality rate when 
compared to other veterans or the general U.S. population. Specific causes of death that were 
significantly higher include those related to substance use and mental health, highlighting the 
importance of integrated treatment and recovery services for patients with record of one or more 
opioid overdose. The significant increase in suicide deaths among veterans, especially among 
those with history of a prior overdose, supports the need for continued mental health screenings. 
These findings highlight the need for additional research examining substance use, in particular 
polysubstance use and associated risk for subsequent mortality among persons with history of 
one or more nonfatal overdose. Future research should consider whether associations identified 
in these analyses are different for patients from other health care systems or for those without 
history of U.S. military service.  
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4.2 Introduction 
 
Overdoses have surged in the past decade and are now the leading cause of accidental death in 
the United States.  More than 60% of overdose deaths across the nation can be attributed to 
opioids[1] [2-5]. Between 2007 and 2017 the opioid overdose death rate more than doubled, 
from 6.1 per 100,000 to 14.9 per 100,000 [6]. Around the same time, nonfatal opioid overdoses 
resulting in inpatient and emergency department visits substantially increased, by more than 60% 
and 99% respectively[7]. The rise in opioid overdoses across the United States has been 
estimated to cost more than $740 million annually [8]. Despite the recent surge of nonfatal 
overdoses and associated mortality associated with opioid abuse/misuse, little is known 
regarding the patterns of mortality following a nonfatal opioid overdose.  
People who inject drugs (PWID), people diagnosed with an opioid use disorder (OUD) and those 
taking more than 90 morphine milligram equivalent (MME) are at highest risk for experiencing 
an opioid overdose [9-12]. Although overdoses are the leading cause of death among PWID, 
research has found that PWID more often die from infection-related causes such as human 
immunodeficiency virus (HIV), Hepatitis C (HCV), and other substance-related deaths [13-15]. 
Similarly, research suggests that people with an OUD more often die from infectious disease and 
liver disease when compared to the general population [13, 16]. Patients taking a high volume of 
MME are often suffering from terminal cancer or chronic diseases associated with severe pain 
[9, 12, 17]. Several public health interventions have been developed to encourage safer 
prescribing practices and educate patients on opioid use, especially for those with high MME 
such as those with chronic non-cancer pain [9, 18]. Although many of these programs have been 
found to reduce the supply of prescription opioids [11], there is still little known regarding the 
complex nature of overdose and subsequent mortality.  Research among Medicaid enrollees 
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suggests that mortality following a nonfatal overdose are often associated with substances, 
suicide, cancer, and the circulatory system however, cause-specific mortality among veterans 
using VHA services has yet to be examined [19].  The overarching objective of this study is to 
assess the cause specific mortality among veterans with a documented nonfatal opioid overdose. 
In order to describe the mortality for specific causes of deaths among veterans with a nonfatal 
overdose, we will examine the mortality following a nonfatal overdose to a comparison group 
comprised of a 5% random sample of other veterans using VHA services. We will then compare 
the mortality among veterans with a nonfatal opioid overdose to the general population.   
Given previous research examining mortality among veterans with an OUD, we expected 
substance-related deaths to be significantly higher among this population [13, 16, 19-21]. We 
also expected suicide death rates to be substantially higher given that veterans have almost 
double the suicide death rate than the general population and previous research suggest that 
people with a history of a nonfatal overdose had higher suicide death rates [19, 22, 23]. 
Similarly, we expected deaths attributed to hepatitis to be significantly higher among our veteran 
cohort, given that prevalence of hepatitis is two-times higher than non-veterans and is higher 
among those with a history of drug use [13, 16, 24-26].   
4.3 Methods 
In order to determine mortality following a nonfatal overdose among veterans, we examined 
causes of death linking clinical and mortality files from the Veterans Health Administration 
(VHA), which is the largest integrated healthcare provider in the United States. We extracted 
records on individuals with a documented opioid overdose between January 1, 2011 and 
September 30, 2015 and identified corresponding causes of death, if any, among this cohort.  
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The study cohort examined clinical and death records for 10,522,835 records to identify veterans 
with a documented opioid overdose and veterans with no documented overdose for the 
comparison group. Veterans were identified as having an opioid overdose using clinical records 
from the VHA Corporate Data Warehouse (CDW)[27].  CDW records were linked with the 
VA/DoD Suicide Data Repository, using Social Security Numbers (SSNs)[28, 29].  Sex and age 
were extracted from the SDR and CDW. Age was fixed and determined at the start of the study 
period. Age-adjusted mortality rates for each cause of death of interest were pulled from the 
Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic 
Research (CDC WONDER) Detailed Compressed Mortality Files from 2011 through 2015 [6]. 
To more precisely compare age-adjusted mortality rates with the veteran population we pulled 
age-adjusted rates among 15-84 year old U.S. residents using CDC WONDER. 
This study was reviewed and approved by the Institutional Review Board at the Syracuse VA 
Medical Center, New York. 
Study sample 
A nonfatal opioid overdose was identified using International Classification of Disease, Ninth 
Edition (ICD-9) codes: 965.00-965.02, 965.09, E850.0-E850.2 and ICD Tenth Edition (ICD-10) 
codes: X40-X44, X60-X64, X85, Y10-Y14 with secondary axis codes: T40.0-T40.4 and T40.6. 
The first opioid overdose documented in the clinical records was used as the index overdose. 
Those who died from a fatal index overdose were excluded from analyses. 
A control group was constructed by extracting a 5% random sample of veterans, stratified by sex 
and age. Age was collapsed into three categories: ages 18-44, 45-64 and over 65 years old. 
Pulling a stratified random sample allowed the control group to be similar in composition to 
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those with a nonfatal overdose[30]. Given that VHA users are primarily older males, we 
intentionally stratified by sex and age to reduce potential bias that may influence observed 
mortality among the control group. The use of stratified random sample control populations has 
been used in previous research among the VHA patient population [20, 31, 32]. 
Exclusion criteria  
The study cohort was restricted to veterans between 18 and 90 years old. We excluded patients 
that had no follow-up visits within one year of the first overdose event or had a nonfatal 
overdose in the last three months of the study period (October 1, 2015 - December 1, 2015). This 
mitigated potential bias among those with less than three months of risk for mortality. After 
applying this inclusion and exclusion criteria, 8,370 veterans were identified for the nonfatal 
overdose group and 325,073 veterans with no documented overdose as the comparison group.  
Mortality  
We evaluated mortality from January 1, 2011 through December 31, 2015. Follow-up for the 
study ended the day the veteran died or the end of the study period, whichever occurred first. In 
addition to all-cause mortality, cause-specific mortality was considered for the following: all 
external causes of death, suicide, homicide, accidents, substance-related deaths, drug-related 
deaths, alcohol-related deaths, infectious, viral hepatitis, human immunodeficiency virus (HIV), 
circulatory system, respiratory system, influenza, chronic respiratory disease, digestive system, 
cirrhosis and alcoholic liver disease and cancers. Specific types of cancers were categorized into 
the following groups using the International Classification of Diseases for Oncology[33]: lung 
and bronchus, liver and intrahepatic bile duct, digestive system cancers, which included 
esophageal, stomach, small intestine, colon, rectal, anal, gallbladder and pancreatic cancers, 
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lymphoma and leukemia and other cancers. (See Supplement Table 1 for the full list of cause-
specific mortality and corresponding ICD-10 codes). 
Analysis  
We identified person-years of follow-up and mortality rates per 10,000 person-years for the 
entire cohort to compare mortality among veterans with a history of nonfatal overdose to a 
comparison group of veterans. Crude death rates were calculated and mortality rates were 
estimated using Cox proportional hazard models, adjusting for age and sex. Survival curves were 
relatively close, indicating the hazard ratio remained constant over time [34]. Adjusted hazard 
ratios [aHR] and corresponding 95% confidence interval [CI] were calculated for cause-specific 
mortality.  
We calculated the standardized mortality rate ratios (SMRs) to compare the observed number of 
deaths among our overdose cohort to the number of expected number based on rates of mortality 
among members of the U.S. general population [35, 36].  The expected number of deaths was 
calculated using age-adjusted mortality rates from CDC WONDER and corresponding cohort 
size[6]. 
Alpha was set to 0.05 for all statistical tests. We analyzed data using SAS Enterprise Grid 
software (version 5.1, SAS Institute Inc.). 
4.4 Results 
This study identified 8,370 veterans with a history of nonfatal opioid overdose and a total follow-
up of 39,207 person-years. Among this cohort of veterans with history of a nonfatal overdose, 
approximately 17.4% (n=1,453) experienced death during the follow-up period. The proportion 
of veterans who died following a nonfatal overdose was similar to the proportion of veterans 
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who died in the control group (17.6%, n=57,099). Despite the similar proportion of deaths 
among each group, there were distinct differences in cause-specific mortality rates and 
corresponding SMRs. The overall crude mortality rate for veterans with a prior overdose was 
370.6 per 10,000 person-years and for the control group was 384.1 per 100,000 person-years. 
Compared to the control group, veterans with a nonfatal opioid overdose had a higher risk of all-
cause mortality after adjusting for age and gender (aHR 1.5; 95% CI 1.4-1.5). (Table 1) 
The most common causes of death among veterans with a prior nonfatal overdose were disorders 
of the circulatory system (26.7%), cancer (19.3%), respiratory disorders (13.1%), and drug-
related deaths (11.6%).  The veteran cohort with a prior nonfatal overdose was more than six 
times likely to die from substance-related diseases (aHR [Adjusted Hazard Ratio] 5.0, 95% CI [ 
Confidence Interval]: 4.4-5.8) and more than six times (aHR 6.9, 95% CI 5.8-8.1) likely to die 
from drug-related diseases compared to their veteran peers. These veterans were more than three 
times as likely to die from hepatitis (aHR 3.2, 95% CI: 2.1-4.9) and cirrhosis or alcoholic liver 
disease than their veteran peers (aHR 3.1, 95% CI: 2.4-3.9). Veterans with a prior overdose were 
also more than two times more likely to die from suicide than their veteran peers (aHR 2.2, 95% 
CI: 1.6-3.1). Further, these veterans were twice as likely to die of diseases associated with the 
digestive system (aHR 2.3, 95% CI: 1.9-2.8), chronic respiratory disease (aHR 2.2, 95% CI: 1.6-
3.1) and HIV (aHR 2.6, 95% CI: 1.3-5.4). 
 Similarly, they had an elevated risk of death from viral hepatitis (aHR 3.2, 95% CI 2.1-4.9) and 
cirrhosis and alcoholic liver disease (aHR 3.1, 95% CI 2.4-3.9). These veterans had a higher risk 
of death attributed to HIV (aHR 2.6, 95% CI 1.3-5.4), cancer of the liver or intrahepatic bile duct 
(aHR 2.3, 95% CI 1.7-3.2), or death associated with the digestive system (aHR 2.3, 95% CI 2.3, 
95% CI 1.9-2.8). Of note, death from suicide was markedly higher among veterans with a prior 
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nonfatal overdose compared to the control group of veterans (aHR 2.2, 95% CI 1.6-3.1). 
Conversely, veterans with history of an overdose were significantly less likely to die from 
lymphoma or leukemia (aHR 0.5, 95% CI 0.2-0.9) compared to veterans in the control group.  
Among cause-specific mortalities assessed and compared to the US population, SMRs were 
more than eight times higher among veterans with a prior overdose. SMRs were highest for 
deaths associated with substances (114.0, 95% CI: 98.8-128.7); including drugs (139.3, 95% CI: 
118.6-160.7) and alcohol (72.7, 95% CI: 53.5-92.4). SMRs for viral hepatitis (107.4, 95% CI: 
65.5-152.7) and liver cancers (68.2, 95% CI: 47.9-88.7) were substantially higher among 
veterans with history of a nonfatal opioid overdose. Other cause-specific disease that were 
elevated in this population include HIV (34.9, 95% CI: 10.7-58.9), suicide (29.0, 95% CI: 20.0-
38.2), and deaths related to the digestive system (45.2, 95% CI: 36.7-53.7). (Table 2) 
4.5 Discussion 
Veterans with a documented nonfatal opioid overdose died at 26 times the rate of the general 
U.S. population aged 15-84 years. Moreover, mortality was markedly higher among veterans 
with a prior nonfatal overdose when compared to a comparison population of veterans who use 
VHA services or the general U.S. population (aHR 1.46, 95% CI: 1.39-1.54). These findings 
suggest that excess mortality among veterans with a prior nonfatal overdose may be associated 
with patterns and consequences of substance use.  Mortality associated with substance use for 
veterans with a prior nonfatal overdose was significantly elevated among those with a prior 
nonfatal overdose. The rate of alcohol-related deaths was 72 times higher than the rate of 
alcohol-related deaths in the general population.  
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Similarly, veterans with a prior nonfatal overdose had noticeably higher rates of death compared 
to other veterans, specifically for deaths associated with drugs (aHR 6.85 95% CI: 5.79-8.09), 
viral hepatitis (aHR 3.22, 95% CI: 2.11-4.93), cirrhosis and alcoholic liver disease (aHR 3.05, 
95% CI 2.38-3.90). These findings suggest excess mortality among veterans with a nonfatal 
overdose can be largely attributed to substance abuse. Although deaths associated with substance 
use accounted for a majority of deaths, disease of the digestive and respiratory system were 
elevated in this population as well. Additional research is need to understand the intersection of 
certain comorbidities related to the digestive system and overdose risk.  
There were some distinct differences when comparing results from this study to an existing study 
examining mortality following a nonfatal overdose among a sample of Medicaid enrollees [19]. 
The all-cause SMR and drug-related deaths were similar between both the veteran population 
and Medicaid enrollees. In general, the cause-specific deaths listed in both studies were elevated 
among the veteran population and HIV was the only cause-specific death in both studies that was 
lower among the Medicaid population. The most notable difference in our study was the SMR 
for alcohol-related deaths, the veteran population had an SMR more than seven times higher than 
the study article. Deaths associated with cirrhosis and alcoholic liver disease were more than four 
times higher and deaths associated with viral hepatitis were more than three times higher. This 
finding may be attributed to high rates of HCV among veterans from the Vietnam Era [24-26].  
These findings parallel previous research suggesting a deeper understanding of the complex 
relationship between overdose and self-harm [23, 37-39]. Importantly, deaths from suicide were 
markedly higher among our cohort of veterans with a prior opioid overdose compared to the 
general population and a random sample of veterans from the VHA using population. This 
finding alone suggests the need for continued support and comprehensive services aimed at 
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reducing suicide among veterans.  Mental health services, such as post-discharge psychiatric care 
may benefit patients with history a nonfatal overdose [40-42]. A documented overdose may 
provide opportunities to initiate treatment or other prevention programs such as naloxone 
distribution or provide mental health screening given the elevated mortality associated with 
suicide and substance-related deaths.  
Strengths and limitations  
Although this study utilized data from one of the nation’s largest healthcare networks, analyses 
were contingent on patients seeking medical care for healthcare needs such as an overdose. The 
large sample size provided the statistical power needed to detect differences in risk for mortality. 
Despite the large sample size, this study had several limitations. Previous studies have shown 
that barriers often impede healthcare treatment for OUD, which could influence findings from 
this study[43].  Results from this study may underestimate the magnitude of nonfatal overdoses 
and subsequent mortality among veterans[44]. Furthermore, these results may not be 
generalizable to the US population given the heterogeneous composition of veterans seeking 
healthcare [45-47].  
Conclusion 
Given the rise in opioid overdoses across the US, there is an urgent need to understand excess 
mortality among people who experience a nonfatal overdose to inform future clinical and public 
health efforts. Veterans with a history of nonfatal overdose are significantly more likely to die 
from any cause, specifically deaths associated with substance use and suicide. Additional 
research is needed to determine the relationship between psychiatric diagnoses, substance use 
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and overdose risk over time. These findings underscore the need for coordinated health care, 
with particular emphasis on mental health care among those with a prior overdose.  
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Table 1. Mortality rate (per 10,000 person-years) among veterans with a nonfatal index OD (n=8,370) compared to a 5% stratified random sample of veterans 
(n=325,073) a 
  Nonfatal OD Control group  
Hazard 
ratio of 
mortality 
95% CI 
Hazard 
Ratio 
Adjusted 
Hazard 
ratio of 
mortality b 
95% CI 
Adjusted 
Hazard 
Ratio b p-value  Cause of death 
No. of 
deaths 
Crude mortality  
rate 
No. of 
deaths 
Crude 
mortality  
rate 
Opioid overdose 59 15.05 
 
- - - - - - 
External Cause of death 69 17.60 1,509 10.15 1.74* (1.36-2.21) 1.82* (1.43-2.32) <0.001 
Suicide 39 9.95 651 4.38 2.27* (1.65-3.14) 2.24* (1.62-3.10) <0.001 
Homicide 5 1.28 98 0.66 1.93 (0.79-4.75) 1.71 (0.70-4.23) 0.24 
Accidents 25 6.38 760 5.11 1.25 (0.84-1.86) 1.43 (0.96-2.13) 0.08 
Substance-related 223 56.88 1,474 9.91 5.74* (4.98-6.61) 5.03* (4.36-5.80) <0.001 
Drug-related  169 43.10 871 5.86 7.36* (6.24-8.68) 6.85* (5.79-8.09) <0.001 
Alcohol-related 54 13.77 603 4.06 3.40* (2.57-4.49) 2.73* (2.06-3.61) <0.001 
Infectious  55 14.03 1,393 9.37 1.50* (1.14-1.96) 1.89* (1.44-2.49) <0.001 
Viral hepatitis 24 6.12 203 1.37 4.48* (2.94-6.84) 3.22* (2.11-4.93) <0.001 
HIV 8 2.04 83 0.56 3.66* (1.77-7.56) 2.63* (1.27-5.44) 0.01 
Circulatory system 388 98.96 18,312 123.17 0.80* (0.73-0.89) 1.29* (1.16-1.42) <0.001 
Respiratory system 191 48.72 6,730 45.27 1.08 (0.93-1.24) 1.87* (1.61-2.16) <0.001 
Influenza & pneumonia 23 5.87 1,219 8.20 0.72 (0.47-1.08) 1.32 (0.87-2.00) 0.19 
Chronic respiratory disease 139 35.45 4,051 27.25 1.30* (1.10-1.54) 2.18* (1.83-2.58) <0.001 
Digestive system 109 27.80 2,036 13.69 2.03* (1.68-2.46) 2.27* (1.87-2.75) <0.001 
Cirrhosis & alcoholic liver disease 70 17.85 763 5.13 3.48* (2.72-4.44) 3.05* (2.38-3.90) <0.001 
Cancers 280 71.42 14,585 98.10 0.73* (0.65-0.82) 1.00 (0.88-1.12) 0.97 
Lung & bronchus 80 20.40 4,347 29.24 0.70* (0.56-0.87) 0.90 (0.72-1.13) 0.38 
Liver & intrahepatic bile duct 43 10.97 699 4.70 2.33* (1.71-3.17) 2.31* (1.69-3.16) <0.001 
Digestive system 42 10.71 2,780 18.70 0.57* (0.42-0.78) 0.77 (0.57-1.05) 0.09 
Lymphoma & leukemia  9 2.30 1,116 7.51 0.31* (0.16-0.59) 0.47* (0.24-0.90) 0.03 
Other cancers 106 27.04 5,643 37.96 0.71* (0.59-0.86) 1.06 (0.88-1.29) 0.55 
Any type of death 1,453 370.59 57,099 384.06 0.97 (0.92-1.02) 1.46* (1.39-1.54) <0.001 
Abbreviations: No, Number; CI, Confidence Interval; SMR, Standardized Mortality Rate Ratio; OD, overdose; HIV, human immunodeficiency virus 
a. For those with a nonfatal OD there were 39,207 person-years follow-up. A control group was constructed using a 5% random sample of veterans, stratified by sex 
and age stratum. 
b. Adjusted for age and sex.  
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Table 2. Standardized Mortality Ratios, observed, and expected number of deaths for veterans with a nonfatal index overdose for all causes and selected causes, 2011-2015 
  
Nonfatal OD US Age-adjusted rates a 
Standardized Mortality Rate Ratio 
(95% CI) 
Cause of death No. of deaths Crude mortality  rate 
Expected 
number of 
deaths b 
SMR b 95% CI 
Opioid overdose 59 15.05 0.91 64.73 (48.29-81.38) 
External Cause of death 69 17.60 4.19 16.47 (12.58-20.35) 
Suicide 39 9.95 1.34 29.01 (19.97-38.24) 
Homicide 5 1.28 0.54 9.25 (1.14-17.38) 
Accidents 25 6.38 2.30 10.85 (6.61-15.13) 
Substance-related 223 56.88 1.96 113.96 (98.84-128.71) 
Drug-related  169 43.10 1.21 139.25 (118.62-160.73) 
Alcohol-related 54 13.77 0.74 72.65 (53.51-92.44) 
Infectious  55 14.03 1.65 33.36 (24.52-42.14) 
Viral hepatitis 24 6.12 0.22 107.39 (65.45-152.74) 
HIV 8 2.04 0.23 34.88 (10.68-58.89) 
Circulatory system 388 98.96 15.27 25.41 (22.88-27.94) 
Respiratory system 191 48.72 5.40 35.40 (30.35-40.39) 
Influenza & pneumonia 23 5.87 0.94 24.45 (14.47-34.47) 
Chronic respiratory disease 139 35.45 3.35 41.48 (34.59-48.39) 
Digestive system 109 27.80 2.41 45.15 (36.74-53.72) 
Cirrhosis & alcoholic liver disease 70 17.85 1.07 65.29 (50.09-80.75) 
Cancer 280 71.42 15.29 18.32 (16.17-20.46) 
Lung & bronchus 80 20.40 4.17 19.20 (14.98-23.39) 
Liver & intrahepatic bile duct 43 10.97 0.63 68.23 (47.85-88.65) 
Digestive system 42 10.71 3.14 13.36 (9.33-17.42) 
Lymphoma & leukemia  9 2.30 1.06 8.47 (2.94-14.04) 
Other cancers 106 27.04 6.14 17.27 (13.98-20.55) 
Any type of death 1,453 370.59 55.41 26.22 (24.87-27.57) 
Abbreviations: No, Number; CI, Confidence Interval; SMR, Standardized Mortality Rate Ratio 
   
a. Mortality for US population was from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research data (CDC WONDER).  
b. Mortality rates and expected counts is by using age-adjusted mortality rates among 15-84 year olds.  
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Supplemental Table ICD-10 Codes for cause-specific mortality 
Cause of death ICD-10 Codes For Underlying Cause of Death 
Opioid overdose  X40-X44, X60-X64, X85, Y10-Y14 with secondary axis codes T40.0-T40.4, T40.6 
External Cause of death X60-X84, Y87.0, X85-Y09, Y87.1, V01-X39, X46-X59, Y85-Y86 
Suicide X60-X84, Y87.0 
Homicide X85-Y09, Y87.1 
Accidents V01-X39, X46-X59, Y85-Y86 
Substance-related F11.0-F11.5, F11.7-F11.9, F12.0-F12.5, F12.7-F12.9, F13.0-F13.5, F13.7-F13.9, F14.0-F14.4, 
F14.7-F14.9, F15.0-F15.5, F15.7-F15.9, F16.0-F16.5, F16.7-F16.9, F17.0, F17.3-F17.5, F17.7-
F17.9, F18.0-F18.5, F18.7-F18.9, F19.0-F19.5, F19.7-F19.9, X40–X44, Y10–Y14, F10, G31.2, 
G62.1, I42.6, K29.2, K70, R78.0, X45, Y15 
Drug-related  F11.0-F11.5, F11.7-F11.9, F12.0-F12.5, F12.7-F12.9, F13.0-F13.5, F13.7-F13.9, F14.0-F14.4, 
F14.7-F14.9, F15.0-F15.5, F15.7-F15.9, F16.0-F16.5, F16.7-F16.9, F17.0, F17.3-F17.5, F17.7-
F17.9, F18.0-F18.5, F18.7-F18.9, F19.0-F19.5, F19.7-F19.9, X40–X44, Y10–Y14 
Alcohol-related F10, G31.2, G62.1, I42.6, K29.2, K70, R78.0, X45, Y15 
Infectious  A00-B99 
Viral hepatitis B15-B19 
HIV B20-B24 
Circulatory system I00-I99 
Respiratory system J00-J98 
Influenza & pneumonia J09-J18 
Chronic respiratory disease J40-J47 
Digestive system K00-K92 
Cirrhosis & alcoholic liver 
disease 
K70, K73-74 
Cancer C00-D48 
Lung & bronchus C34 
Liver & intrahepatic bile duct C22 
Digestive system C15-C21, C23-C26 
Lymphoma & leukemia  C82-C85, C91-C95 
Other cancers C00-C14, C27-C33, C35-C81, C86-C90, C96-D48 
Abbreviations: ICD-10, International Classification of Diseases, Tenth Edition 
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5.1. Summary  
This retrospective cohort study consisted of 13,333 patients with a documented opioid overdose, 
of any type, from January 1, 2011 to December 31, 2015. Among our cohort, 4,949 persons 
experienced a fatal overdose during the study period. Of note, we found that mortality from an 
opioid overdose was highest for an individual’s index (i.e. first recorded in the electronic medical 
record) overdose (98.8%, n=4,890), with only 1.2% (n=59) dying on a repeat overdose. Of those 
who survived their first overdose, 31.5% (n=2,659) had one or more repeat overdoses. Among 
those with a repeat overdose, we found that the conditional probability of repeat overdose 
increased in a linear fashion with the number of additional overdoses in the patient’s medical 
records. In other words, the probability of having a fourth overdose was higher than the 
probability of having either a third or second overdose.  
Although the U.S. has been experiencing an increase in overdoses for more than a decade there is 
still a limited understanding of risk for repeat overdose or whether factors associated with 
increased risk for repeat overdose are also associated with risk for overdose mortality. To answer 
these questions, we identified and compared risk factors for different overdose outcomes, 
including repeat overdose, available in VHA’s electronic health record.  
Patients between the ages of 18-64 years were the most likely to have record of a repeat overdose 
or fatal index overdose compared to those with record of only one non-fatal overdose. Men were 
more likely than women to die on their index overdose when compared to either repeat or single 
non-fatal overdose. (OR [odds ratio] 1.57, 95% CI [confidence interval]: 1.34-1.83). Similarly, 
those with a chronic pain diagnosis were more likely to experience either a repeat overdose (OR 
1.15, 95% CI: 1.04-1.27) or fatal index overdose (OR 3.96, 95% CI: 3.56-4.42), when compared 
to those with report of only one non-fatal overdose. Surprisingly, we found that patients with a 
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mental health and substance abuse/dependence diagnosis were more likely to experience a repeat 
overdose and were less likely to die from a fatal index overdose.  We also identified associations 
between patients receiving counseling prior to an overdose and lower likelihood of experiencing 
a fatal overdose (OR 0.35, 95% CI: 0.30-0.40) and those who had been in MAT more than one 
year prior were more likely to experience a fatal index overdose (OR 1.28, 95% CI:1.05-1.55). 
Neither of these factors were significantly associated with repeat overdose.  
Among those with a non-fatal overdose during the study period, we identified significantly 
increased rates for all-cause mortality when compared to risk for death among other veterans 
receiving VHA services. Veterans with record of a non-fatal overdose were five times (aHR 
5.03, 95% CI: 4.36-5.80) more likely to die from substance-related deaths than their veteran 
peers. Furthermore, they were more than three times as likely to die from viral hepatitis (aHR 
3.22, 95% CI: 2.11-4.93) or cirrhosis and alcohol-related liver disease (aHR 3.05, 95% CI: 2.38-
3.90). Despite the higher rate of suicide among veterans who use VHA services [1-3], those with 
a history of an opioid overdose were twice (aHR 2.24, 95% CI: 1.62-3.10) as likely to die from 
suicide as their veteran peers who also used VHA services.  
Standardized mortality rate ratios (SMR) were calculated to identify differences in the number of 
observed deaths to the number of expected deaths for cause-specific mortality in the general U.S. 
population. Of the categories examined, veterans with a non-fatal overdose died at more than 139 
times the rate of drug-related deaths, more than 114 times the rate for substance-related deaths 
and more than 72 times the rate for alcohol-related deaths than the general U.S. population. 
Moreover, veterans with a history of an opioid overdose died at more than 100 times the rate 
from viral hepatitis, more than 68 times the rate of liver and intrahepatic bile duct cancer, and 
more than 65 times the rate for cirrhosis and alcoholic-related liver disease than the general 
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population. Overall, we found that veterans with a history of non-fatal overdose died at 
approximately 26 times the rate of all-cause mortality than observed in the general population. 
Overall, these findings highlight the need for additional public health and clinical interventions 
for those at risk of overdose. Prevention programs designed to reduce opioid overdose mortality 
should focus on primary prevention efforts, such as reaching veterans who may not have been 
identified as having a substance abuse or dependence problem and should tailor these programs 
to engage veterans who are young to middle aged adults. These findings suggest healthcare 
providers and health system administrators should prepare for a rise in patients with repeat 
overdose history and should work to coordinate these patients with mental and physical health 
care as needed. Lastly, these findings suggest a need to address excess mortality risk among 
people with a history of non-fatal overdose. Findings from this project describe the magnitude of 
excess mortality among people with a history of a non-fatal overdose, especially causes of death 
related to substances; including drugs or alcohol.  
5.2 Significance 
In the United States, the opioid overdose death rate nearly doubled in four years between 2013 to 
2017 (7.9 to 14.0 per 100,000), highlighting the urgent need to understand ways public health 
and clinical efforts can address rising morbidity and mortality associated with opioid abuse and 
misuse [4-9]. This study sought to identify the potential differences in risk for non-fatal, repeated 
and fatal overdose, which are all of growing concern. To date, little is known about the 
magnitude of repeat overdoses that occur within a clinical setting and the overdose event that is 
associated with the highest overdose mortality.  
Understanding risk factors for fatal overdose and repeat overdose can inform public health and 
clinical efforts to combat the rise in mortality and morbidity associated with opioid overdoses. 
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The project specifically assessed the number of non-fatal overdoses and risk for mortality or 
repeated events. Results from this project parallel findings from previous research, which 
suggests the need for additional mental health programs and treatment for those who experience 
an opioid overdose. These findings also underscore the need to amplify primary prevention 
efforts targeted to those who may not have experienced a previous overdose, specifically those 
between the ages of 18 and 64 years.  
This study was not without limitations. First, we were only able to examine opioid overdoses that 
were documented in VHA’s clinical or mortality records. It is possible that the true number of 
opioid overdoses among this patient population was underestimated. Moreover, patients may 
have sought health services not associated with VHA, which could also bias results and limit 
consideration of associated characteristics. This study was conducted using data from veterans 
using VHA healthcare services, who often report a greater number of physical and mental health 
conditions compared to the general population [10, 11]. It is possible that patients with different 
physical and mental health comorbidities are associated with differential patterns of health care 
services and likelihood that overdose history is assessed and recorded. These analyses were 
conducted among patients seeking medical care which could lead to Berksonian bias, due to the 
difference in overall health among populations studied [12]. However, using comparison groups 
and stratifying by potential confounding features such as sex and age aided to reduce potential 
bias that may occur.  Lastly, using clinical records with mortality files could have resulted in a 
missed deaths resulting in an underestimate of true mortality. However, records were required to 
match fully on SSN and 80-90% on additional demographics such as name, date of birth, and sex 
[2, 13, 14]. Diagnostic codes in clinical records are not always a true representation the number 
of patients meeting diagnostic criteria. Clinical records are reliant on medical professionals 
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inputting them into the electronic health records therefore certain diagnostic codes, in particular 
the social codes, may be underutilized and lead to an underestimate in the patient population [15, 
16]. 
Although this study used clinical records which have inherent limitations, to the best of our 
knowledge, this was the first study to explore multiple overdose outcomes and compare risk 
factors for category of overdose using a comprehensive list of potential medical and contextual 
characteristics including demographic, chronic pain diagnoses, mental health diagnoses, and 
social codes, which served as indicators of social determinants of health. Findings from this 
study could be useful in informing clinical tools developed by the VA, such as a clinical 
dashboard, which is used to identify patients at risk for an adverse event related to opioids, by 
integrating contextual factors that may increase a patients risk for experiencing an overdose [17-
20].  
5.3 Future research 
These results indicate the need for additional research, specifically among those with co-
occurring mental health and substance use disorders. While there are many public health 
interventions aimed at reducing the morbidity and mortality associated with overdoses, they have 
primarily focused on reducing the excess supply of prescription opioids. While some public 
health prevention efforts have demonstrated a reduction in overdose death, such as the 
implementation of prescription drug monitoring programs or the development of chronic pain 
guidelines, some researchers suggest this has pushed individuals to seek more potent non-
prescription opioid options increasing risk for overdose morbidity and mortality [21-23]. 
Furthermore, public health and clinical interventions have been primarily developed to reduce 
the supply of opioids rather than reducing demand. Additional research is needed on initiation of 
96 
 
substance abuse and misuse and motivation for initial misuse. Findings from this study suggest 
that additional comorbidities, specifically mental health comorbidities, may be the underlying 
factors driving the current overdose crisis and in turn may be factors associated initial misuse or 
abuse. While safer prescribing practices are necessary to mitigate initial abuse or misuse, a high-
level of stigma is present among people with an opioid use disorder (OUD) [24, 25].  Stigma-
reduction is essential in supporting individuals with a history of substance abuse or dependence, 
including reducing the stigma surround seeking treatment for the disease [26].  Although there is 
a prolific amount of research showing the effectiveness of Medication-Assisted Treatment 
(MAT) for OUD, additional barriers often impede patients from receiving necessary treatment. 
Infrastructure barriers such as provider willingness and access to providers who can prescribe 
MAT often deter patients from receiving treatment [20, 26-28].  Given our findings, which show 
that mortality is highest for the first documented overdose, there is an urgent need to remove 
potential barriers that may impede patients from seeking medical resources needed.   
Future studies should also examine the conditional probability of repeat overdose and identify 
the overdose event that is associated with highest mortality in other populations. Furthermore, 
additional research is needed to elucidate the relationship between psychiatric comorbidities and 
overdose risk. Mental health diagnosis and related conditions, including substance abuse or 
dependence, are suggested to be the driving factors for the rise in opioid overdoses. Because of 
this, additional research is also needed to understand the best treatment for individuals with co-
occurring mental health diagnoses or a history of polysubstance use.  
5.4. Conclusions 
Understanding risk of experiencing a fatal overdose or repeated overdose is necessary in order to 
curb the current rise in fatal and non-fatal overdoses. These findings underscore the need for 
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amplified prevention efforts targeted to those without a history of overdose. Furthermore, these 
results suggest that healthcare systems should be ready for a rise in the number of patients seen 
for a repeat overdose. While these results suggest that patients with a repeat overdose may be in 
need of additional clinical services, coordinated health care is needed among those with a prior 
overdose. In order to tackle this multifaceted issue, additional primary care services are needed 
in conjunction with mental health care to address the potential comorbidities among those with a 
documented or suspected overdose. In conclusion, this study demonstrates that opioid overdoses 
remain a significant public health problem with additional research needed however, the current 
public health crisis is not driven solely by opioids, rather this appears to be mental health needs 
and associated crises. Health systems, clinical health providers, and others seeking to decrease 
deaths resulting from opioid overdose, are encouraged to systematically assess for and intervene 
on symptoms associated with mental health disorders.  
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APPENDIX A 
Diagnostic codes used for opioid overdoses recorded in the EHR 
Type of 
overdose 
ICD-9 ICD-10 
   
Opioid 
overdose 
hospitalization 
965.00 (Opium) 
965.01 (Heroin) 
965.02  (Methadone) 
965.09 (Other opiates/narcotics) 
OR 
E850.0 (Accidental: Heroin 
E850.1 (Accidental: Methadone) 
E850.2 (Accidental: Other opiates) 
T40.0X Opium  
T40.1X Heroin 
T40.2X Other opioids 
T40.3X Methadone 
T40.4X Synthetic narcotics 
T40.60X Unspecified narcotics 
T40.69X Other narcotics 
 
And a 6th character of 1,2,3,or 4 
 
   
Opioid 
overdose 
mortality  
 Underlying cause of death code: 
X40-X44 (accidental), X60-X64 
(intentional/self-harm), X85 
(assault/homicide), Y10-Y14 
(undetermined)  
 
And a contribution cause of death code 
T40.0-T40.4, T40.6 
 
Abbreviations: ICD-9, International Classification of Diseases, Ninth Revision; ICD-10, 
International Classification of Diseases, Tenth Revision; EHR, electronic health record 
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APPENDIX B 
Variables of interest among veterans with an opioid overdose 
Characteristic Variable  Related ICD codes 
Sex Sex (1=male, 0=female)  Used last entered value 
Age Age (Continuous)  Age as of January 1, 2011 
Date of visit V_date (in SAS date9. format)  Time period 01/01/2011-12/31/2015 
Psychosocial & related mental health diagnoses 
Any mental health 
diagnosis mh_dx (1=yes, 0=no) 
ICD-9: 290.00 to 319.99, excluding tobacco codes starting with 
305  
ICD-10: F00 to F99, excluding tobacco codes starting with F17 
Anxiety anx_dx (1=yes, 0=no) ICD-9: 300 ICD-10: F40, F41 
Depression dep_dx (1=yes, 0=no) ICD-9: 296.2, 296.3, 300.4, 311  ICD-10: F32, F33, F34.1 
Bipolar bip_dx (1=yes, 0=no) ICD-9: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8 ICD-10: F31 
PTSD ptsd (1=yes, 0=no) ICD-9: 309.81 ICD-10: F43.1 
Adjustment disorder adj_dx (1=yes, 0=no) ICD-9: 309.0, 309.24, 309.28, 309.3, 309.4, 309.9  ICD-10: F43.20- F43.25 
Schizophrenia or other 
psychotic disorders sch_dx (1=yes, 0=no) 
ICD-9: 295.90, 295.40, 295.70, 297.1, 297.3, 298.8, 293.81, 
293.82, 298.9  
ICD-10: F20.9, F20.81, F25.0, F25.1, F22, F24, F23, F06.2, 
F06.0, F29) 
Traumatic stress trst_dx (1=yes, 0=no) ICD-9: 308.9, 309.89, 309.9 ICD-10: F43.0 F43.8, F43.9 
Personality disorder per_dx (1=yes, 0=no) 
ICD-9: 301.83, 301.7, 301.81, 301.50, 301.4, 301.82, 301.6, 
301.0, 301.20, 310.1 301.9  
ICD-10: F60, F61 
Opioid 
abuse/dependence  op_dx (1=yes, 0=no) 
ICD-9 codes: 304.0, 304.7, 305.5 
ICD-10 codes: F11 
Alcohol 
abuse/dependence  
alc_dx (1=yes, 0=no) ICD-9: 303, 305.0  
ICD-10: F10 
Cannabis 
abuse/dependence  
can_dx (1=yes, 0=no) ICD-9: 304.3, 305.2 
ICD-10: F12 
Sedative, hypnotics, or 
anxiolytic 
abuse/dependence 
sha_dx (1=yes, 0=no) ICD-9: 304.1, 305.4 
ICD-10: F13 
Cocaine 
abuse/dependence 
coc_dx (1=yes, 0=no) ICD-9: 304.2, 305.6 
ICD-10: F14 
Other stimulant 
abuse/dependence 
stm_dx (1=yes, 0=no) ICD-9: 304.4, 305.7 
ICD-10: F15 
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Hallucinogen 
abuse/dependence  
hal_dx (1=yes, 0=no) ICD-9: 304.5, 305.3  
ICD-10: F16 
Any substance 
abuse/dependence  
anysub_dx (1=yes, 
0=no) Any diagnosis for substance abuse/dependence  
Polysubstance 
abuse/dependence 
polysub_dx (1=yes, 
0=no) More than 1 diagnosis for substance abuse/dependence 
TBI tbi_dx (1=yes, 0=no) 
ICD-9: 800.0-801.9, 803.0-804.9, 850.0-854.1, 950.1-950.3, 
995.55, 959.01  
ICD-10: S02.0, S02.1, S02.8, S02.91, S04.02, S04.03, S04.04, 
S06, S07.1, T74.4  
Medication-Assisted Treatment (MAT) 
Record of MAT MAT 
 
Using stop code 523 (primary or secondary stop code) to identify 
MAT services 
Chronic pain before index OD 
Back pain b_pain (1=yes, 0=no) ICD-9: 720.0-724.9 
ICD-10: M45.9- M46.1, M46.90, M47.812, M47.12, M47.814, 
M47.817, M48.20, M48.10, M48.30, M48.9, M50.20, M51.9, 
M50.30, M51.34-M51.37, M48.02, M54.2, M53.0, M53.1, 
M54.12, M54.13,M43.6, M54.02, M67.88, M53.82, M54.6, 
M54.5, M54.30, M54.14-M54.17, M54.89-M54.9, M43.27, 
M43.28, M53.2X7, M53.3, M54.08, M43.8X9, M53.9 
Arthritis  a_pain (1=yes, 0=no) ICD-9: 710.0-739.9, excluding back pain codes 
ICD-10: M00-M02, M36.2, M36.3, M12, M35.3, M15, M16-
M19, M05-M08, M1A, M10-M14 
Migraines m_pain (1=yes, 0=no) ICD-9: 346.0-346.9 
ICD-10:G43.0, G43.1, G43.4, G43.5, G43.6, G43.7, G43.8, 
G43.9, G43.A, G43.B, G43.C, G43.D 
Headaches or tension 
headaches 
h_pain (1=yes, 0=no) ICD-9: 784.0 and 307.81 
ICD-10: G44.1, R51, G44.209 
Psychogenic p_pain (1=yes, 0=no) ICD-9: 307.80 and 307.89 
ICD-10: F45.41, F45.42 
Neuropathy n_pain (1=yes, 0=no) ICD-9: 355.0, 355.9, 356.0, 357.2, 357.9 
ICD-10:G57.00, G58.9, G60, E08.42, E09.42, E10.42, E11.42, 
E13.42, G61.9 
Fibromyalgia f_pain (1=yes, 0=no) ICD-9: 729.1 
ICD-10: M60.9, M79.1, M79.7 
Any chronic pain 
diagnosis 
chr_dx (1=yes, 0=no) Any of the diagnoses for chronic pain  
Social determinants of health (SDoH) codes prior to index OD 
Problems related to 
housing and economic 
circumstances 
Prob_econ 
(1=yes, 0=no) 
ICD-9:  V60.0, V60.1, V60.89, V60.6, V60.2, V60.9 
ICD-10: Z59 (Z59.0-Z59.9) 
Problems related to 
support group, 
including family and 
relationships 
Prob_supp 
(1=yes, 0=no) 
ICD-9:  V61.0, V61.05, V61.8, V61.01, V61.06, V61.07, 
V61.08, V62.82, V61.03, V61.49, V61.02, V61.41, V61.3, 
V61.04, V61.09, V61.8, V61.9 
ICD-10: Z63 (Z63.0-Z63.9) 
Problems related to 
social environment 
Prob_soenv 
(1=yes, 0=no) 
ICD-9:  V60.3, V62.4, V62.89 
ICD-10: Z60.0, Z60.2, Z60.3, Z60.4, Z60.5, Z60.8, Z60.9 
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Problems related to 
upbringing 
Prob_upbr 
(1=yes, 0=no) 
ICD-9:  V61.29, V61.8, V60.81 
ICD-10: Z62.0, Z62.1, Z62.2, Z62.3, Z62.6, Z62.8 
Problems related to 
environmental 
psychosocial 
circumstances 
Prob_enpsych 
(1=yes, 0=no) 
ICD-9:  V62.5, V62.89, V62.81, V62.9 
ICD-10: Z65.0, Z65.1, Z65.2, Z65.3, Z65.4, Z65.5, Z65.8, Z65.9 
Problems related to 
abuse  
Prob_abuse 
(1=yes, 0=no) 
ICD-9:  V61.21, V61.22, V62.83, V61.11, V61.12, V65.49 
ICD-10: Z69.0, Z69.01, Z69.02, Z69.1, Z69.8 
Counseling services Prob_coun 
(1=yes, 0=no) 
ICD-9:  V65.49, V61.2, V61.1, V65.40, V65.9 
ICD-10: Z71.81, Z71.89, Z71.9 
Other problems related 
to mental and behavior 
Prob_menbeh 
(1=yes, 0=no) 
ICD-9:  V40.0, V40.2, V40.3, V40.31, V40.39, V40.9 
ICD-10: F48.9, F69 
Any SDoH any_sdoh  
(1=yes, 0=no) 
Any of the above SDoH codes captured before index OD 
Abbreviations: ICD, International Classification of Disease; ICD-9, International Classification of Disease, Ninth 
Edition; ICD-10, International Classification of Disease, Tenth Edition; PTSD, Post-traumatic stress disorder; TBI, 
Traumatic Brian Injury; MAT, Medication-Assisted Treatment; OD, overdose; SDoH, social determinant of health 
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APPENDIX C 
 
Diagnostic codes used to classify indicators of social determinants of health 
Description Description  ICD code  
Problems related to housing 
and economic circumstances 
• Homelessness 
• Inadequate housing 
• Discord with neighbors, lodgers and 
landlord 
• Problems related to living in residential 
institution 
• Lack of adequate food and safe drinking 
water 
• Extreme poverty 
• Low income 
• Insufficient social insurance and welfare 
support 
• Other problems related to housing and 
economic circumstances 
• Problem related to housing and economic 
circumstances, unspecified 
ICD-9:  V60.0, V60.1, V60.89, 
V60.6, V60.2, V60.9 
ICD-10: Z59 (Z59.0-Z59.9) 
Problems related to support 
group, including family and 
relationships 
• Problems in relationship with spouse or 
partner 
• Problems in relationship with in-laws 
• Absence of family member 
• Disappearance and death of family member 
• Disruption of family by separation and 
divorce 
• Dependent relative needing care at home 
• Other stressful life events affecting family 
and household 
• Other specified problems related to primary 
support group 
• Problems related to primary support group, 
unspecified 
ICD-9:  V61.0, V61.05, V61.8, 
V61.01, V61.06, V61.07, V61.08, 
V62.82, V61.03, V61.49, V61.02, 
V61.41, V61.3, V61.04, V61.09, 
V61.8, V61.9 
ICD-10: Z63 (Z63.0-Z63.9) 
Problems related to social 
environment 
• Problems of adjustment to life-cycle 
transitions 
• Problems related to living alone 
• Acculturation difficulty  
• Social exclusion and rejection 
• Target of  (perceived) adverse 
discrimination and persecution 
• Other problems related to social 
environment 
• Problem related to social environment, 
unspecified 
ICD-9:  V60.3, V62.4, V62.89 
ICD-10: Z60.0, Z60.2, Z60.3, 
Z60.4, Z60.5, Z60.8, Z60.9 
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Problems related to 
upbringing 
• Inadequate parental supervision and control 
• Parental overprotection 
• Upbringing away from parents 
• Hostility towards and scapegoating of child 
• Inappropriate (excessive) parental pressure 
• Other specified problems related to 
upbringing 
ICD-9:  V61.29, V61.8, V60.81 
ICD-10: Z62.0, Z62.1, Z62.2, 
Z62.3, Z62.6, Z62.8 
Problems related to 
environmental psychosocial 
circumstances 
• Conviction in civil and criminal 
proceedings without imprisonment 
• Imprisonment and other incarceration 
• Problems related to release from prison 
• Problems related to other legal 
circumstances 
• Victim of crime and terrorism 
• Exposure to disaster, war and other 
hostilities 
• Other specified problems related to 
psychosocial circumstances 
• Problem related to unspecified psychosocial 
circumstances 
ICD-9:  V62.5, V62.89, V62.81, 
V62.9 
ICD-10: Z65.0, Z65.1, Z65.2, 
Z65.3, Z65.4, Z65.5, Z65.8, Z65.9 
Problems related to abuse  • Encounter for mental health services for 
child abuse problems 
• Encounter for mental health services for 
parental child abuse 
• Encounter for mental health services for 
non-parental child abuse 
• Encounter for mental health services for 
spousal or partner abuse problems 
• Encounter for mental health services for 
victim or perpetrator of other abuse 
ICD-9:  V61.21, V61.22, V62.83, 
V61.11, V61.12, V65.49 
ICD-10: Z69.0, Z69.01, Z69.02, 
Z69.1, Z69.8 
Counseling services • Spiritual or religious counseling 
• Other specified counseling 
• Counseling, unspecified 
ICD-9:  V65.49, V61.2, V61.1, 
V65.40, V65.9 
ICD-10: Z71.81, Z71.89, Z71.9 
Other problems related to 
mental and behavior 
• Nonpsychotic  mental disorder, unspecified 
• Unspecified disorder of adult personality 
and behavior 
ICD-9:  V40.0, V40.2, V40.3, 
V40.31, V40.39, V40.9 
ICD-10: F48.9, F69 
Any SDoH Any of the above SDoH codes captured before index OD 
 
Abbreviations: ICD, International Classification of Disease; ICD-9, International Classification of Disease, Ninth 
Edition; ICD-10, International Classification of Disease, Tenth Edition; SDoH, social determinant of health 
 
106 
 
APPENDIX D 
Underlying cause of death codes used for cause-specific mortality 
Cause of death ICD-10 Codes Associated With Underlying Cause of Death 
Opioid overdose  X40-X44, X60-X64, X85, Y10-Y14 with secondary axis codes T40.0-T40.4, T40.6 
External Cause of death X60-X84, Y87.0, X85-Y09, Y87.1, V01-X39, X46-X59, Y85-Y86 
Suicide X60-X84, Y87.0 
Homicide X85-Y09, Y87.1 
Accidents V01-X39, X46-X59, Y85-Y86 
Substance-related F11.0-F11.5, F11.7-F11.9, F12.0-F12.5, F12.7-F12.9, F13.0-F13.5, F13.7-F13.9, 
F14.0-F14.4, F14.7-F14.9, F15.0-F15.5, F15.7-F15.9, F16.0-F16.5, F16.7-F16.9, 
F17.0, F17.3-F17.5, F17.7-F17.9, F18.0-F18.5, F18.7-F18.9, F19.0-F19.5, F19.7-
F19.9, X40–X44, Y10–Y14, F10, G31.2, G62.1, I42.6, K29.2, K70, R78.0, X45, 
Y15 
Drug-related  F11.0-F11.5, F11.7-F11.9, F12.0-F12.5, F12.7-F12.9, F13.0-F13.5, F13.7-F13.9, 
F14.0-F14.4, F14.7-F14.9, F15.0-F15.5, F15.7-F15.9, F16.0-F16.5, F16.7-F16.9, 
F17.0, F17.3-F17.5, F17.7-F17.9, F18.0-F18.5, F18.7-F18.9, F19.0-F19.5, F19.7-
F19.9, X40–X44, Y10–Y14 
Alcohol-related F10, G31.2, G62.1, I42.6, K29.2, K70, R78.0, X45, Y15 
Infectious  A00-B99 
Viral hepatitis B15-B19 
HIV B20-B24 
Circulatory system I00-I99 
Respiratory system J00-J98 
Influenza & pneumonia J09-J18 
Chronic respiratory 
disease 
J40-J47 
Digestive system K00-K92 
Cirrhosis & alcoholic 
liver disease 
K70, K73-74 
Cancer C00-D48 
Lung & bronchus C34 
Liver & intrahepatic bile 
duct 
C22 
Digestive system C15-C21, C23-C26 
Lymphoma & leukemia  C82-C85, C91-C95 
Other cancers C00-C14, C27-C33, C35-C81, C86-C90, C96-D48 
Abbreviations: ICD-10, International Classification of Diseases, Tenth Edition; HIV, human immunodeficiency 
virus 
 
